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1   INTRODUCTION 
 
Cardiovascular disease (CVD) is considered a multifactoral disease. Its mortality rates are 
high and in several countries it is known to be one of the most dominant causes of death. 
Widespread studies, both clinical and epidemiological, have shown that increase in the risk 
of coronary heart disease and heart attack can be attributed to several factors. Abnormal 
level of blood lipid is one of the major risk factors of CVD. There are a number of studies 
that indicate oxidative stress has a role in initiating numerous diseases, including 
cardiovascular disease, hypercholesterolemia, atherosclerosis, and hypertension, (Touyz and 
Schiffrin, 2004; Paravicini and Touyz, 2008; Shah et al, 2008; Harrison and Gongora, 
2009). 
 
There are some evidence that probiotics may reduce the risk of cardiovascular diseases in 
addition to their effect on gastrointestinal disorders and other health benefits. Probiotic 
bacteria have been the subject of interest in both the scientific and the commercial world. 
The reason for this interest lies in the assortment of health effects of these particular types of 
bacteria on humans. Probiotics, which are living microorganisms, could help in wellbeing of 
humans, if consumed in appropriate quantity. Probiotic microorganisms can be found as 
components of foods, dairy products and in the form of supplements or beverages. These 
bacteria and yeasts have been used for many years for fermenting foods. Such useful 
bacteria, especially specific strains of bifidobacteria and lactobacilli, can be found in 
specific food such as yoghurt and milk based products. 
 
Lactobacilli and Bifidobacteria that compromise a chief part of the normal intestinal 
microflora in animals and humans are Gram-positive lactic acid-producing bacteria. The 
gastronomical environment and the microflora that live in it play a significant role in 
maintaining the health of humans. The microflora is comprised of all sorts of bacteria that 
could be potentially useful or damaging to human health. It is, therefore, important to 
maintain a healthy intestinal tract that allows absorption of nutrients, while keeping out 
toxins and pathogens. By consuming probiotics, specifically certain species of 
bifidobacteria and lactobacilli, the balance of flora can be assisted. This balance is created 
through increasing the number of helpful and reducing harmful bacteria in the intestine.  
Consumption of probiotics can also enhance the immune response of the gut and improve its 
function as an important barrier against harmful bacteria. 
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The most conclusive evidence offered for the benefits of probiotics is, probably, their anti-
diarrheal and stool regulating effects (Gionchetti et al, 2000; Levy, 2000; Benchimol and 
Mack, 2004; de Vrese and Marteau, 2007). There is significant evidence that eating 
fermented milk with adequate amounts of live and active yoghurt cultures can reduce 
symptoms of lactose intolerance in humans (Guarner et al, 2005; Parvez et al, 2006; de 
Vrese and Schrezenmeir, 2008).  Studies have shown that individuals suffering from 
rotavirus or travelers’ diarrhea could benefit from probiotics which can reduce its severity 
and the length (Solga, 2003; Tomas et al, 2004; Johnston et al, 2007).  Certain strains of 
probiotics have shown immunomodulatory effect.  They can improve immune defenses of 
the mucosal cells in the intestine through both non-specific and specific effects. Some 
evidence show that certain strains have positive effects on allergy (Kalliomaki and Isolauri, 
2004; Isolauri and Salminen, 2008).  A growing number of studies show that probiotics may 
have positive effect on blood lipid level, as well (Gilliland et al, 1985; Agerholm-Larsen et 
al, 2000; Tamime, 2002; Parvez et al, 2005; Fabian and Elmadfa, 2006). 
 
Probiotics and hypocholesterolemia  
Cholesterol is essential in functioning of the body. It is necessary for formation of certain 
hormones and vitamins, and is an essential component of cell membrane and nerve cells. 
However, high levels of cholesterol or some other lipids could lead to cardiovascular 
disease. While in our body cholesterol is made to keep the required level for different 
functions, our diet also influences the plasma lipids. Many studies have investigated the 
effect of lactic acid bacteria on lipid profile. 
  
One of the first studies on the effect of fermented milk on cholesterol concentration was 
conducted by Mann and Spoerry (Mann and Spoerry, 1974) in Maasai tribes. This initiated 
more studies to investigate the possible relation between cholesterol and fermented milk. 
Several in vitro studies have shown that some strains of LABS such as bifidobacteria and 
lactobacilli, in the presence of bile acids, are capable to assimilate cholesterol. 
 
Probiotic bacteria are able to produce short-chain fatty acids (SCFA) through fermenting 
carbohydrate in food. Production of the SCFA in the gut, could block synthesis of hepatic 
cholesterol or redirect plasma cholesterol toward the liver, and as a result lower the plasma 
cholesterol. Additionally, some strains are able to block cholesterol absorption through 
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deconjugating bile salt, or disrupting cholesterol mechanism through assimilating it directly, 
in the gut. 
 
Evidence from some animal studies, proposes that some fermented milk products are 
capable to reduce cholesterol moderately. However, studies on human have not been 
decisive on their effect on reducing cholesterol or low density lipoprotein (Lewis and 
Burmeister, 2005 Greany et al, 2008; Klein et al, 2008). The inconsistency in results is 
probably due to differences in the bacteria strains, designs of the studies, and confounding 
factors such as intake of fermented milk, which make it difficult to draw a conclusion. 
 
Probiotics and oxidative stress 
Human body posses an antioxidant mechanism for defense as well as a repair system. This 
system which has been developed to defend the body against oxidation destruction is not 
sufficient to avoid damage. However, those foods or supplements which have antioxidant 
properties could be beneficial in decreasing the oxidative injury.  
 
Oxidative stress takes place when the creation of reactive oxygen species (ROS) in a system 
surpasses its ability to neutralize and eradicate them. ROS encompasses non-radicals and 
radicals derived species. These molecules have unpaired electrons and usually are very 
reactive. They are produced in the cell constantly as a result of cell respiration or as 
metabolism by-products. Molecular oxygen and hydroxyl radicals or superoxide anion, 
which are its radical derivatives, in addition to peroxides and transition metals are among 
main free radicals in aerobic cells (Percival, 1998). 
 
A highly complex antioxidant protection system operates in the human body to block 
creation of free radicals. The system has different components such as proteins to seize 
transition metals, enzymes to stop peroxides, and also a mechanism to hunt ROS. When 
biological molecules in the body get oxidized by ROS, disease and tissue damage occur. 
 
Studies on the antioxidant properties of lactobacillus have been conducted recently There 
are studies on the antioxidative ability of some strains of bifidobacteria and lactobacilli 
(Kullisar et al, 2002; Lin and Chang, 2000). Antioxidant activity shown by lactic acid 
bacteria in their intracellular cell-free extract are through different mechanisms including; 
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hunting ROS, chelating ability for metal ion, blocking enzymes activity, and reducing 
ascorbate autoxidation (Lin and Yen, 1999). 
 
The ability of starter cultures to hunt free radicals in fermented milks and other dairy 
products could offer another supply of antioxidants in the body, by giving a chance to 
probiotics to make antioxidant while they are increasing in the GI tract (Ouwehand and 
Salminen, 2002). Depending on the culture applied in each study, the power of antioxidants 
varies.  
 
The evidence about the effect of probiotic yoghurt on lipid profile and oxidative stress 
parameters are not conclusive. Furthermore, in the studies that were conducted, probiotic 
and conventional yoghurt consuming groups were compared. In the present study in 
addition to the two yoghurt groups a third group which did not use fermented products was 
considered. The aim of the present study is to compare the effect of probiotics yoghurt 
containing Lactobacillus acidophilus LA5 and Bifidobacteria lactis BB12 and conventional 
yoghurt on the lipid profile and parameters of oxidative stress in healthy women.  
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2   GOAL AND OBJECTIVES  
2-1  Goal 
The main goal of this study is to compare the effects of consumption of probiotic yoghurt 
containing Lactobacillus acidophilus LA5 and Bifidobacteria lactis BB12, conventional 
yoghurt and not fermented dairy products in the diet, on lipid profile and parameters of 
oxidative stress in healthy women. 
 
2-2  Analytical objectives 
Related to Lipid profile: 
1- To compare the mean concentrations of lipid profile, including total cholesterol, 
triglyceride, LDL cholesterol, HDL cholesterol, total to HDL cholesterol ratio, Apo A, and 
Apo B at the baseline among three groups: groups consuming conventional yoghurt, 
probiotic yoghurt and control group (consuming no fermented dairy products).  
 
2- To compare the mean concentrations of lipid profile within each group at each interval, at 
baseline, after 3 weeks and after 6 weeks.  
 
3- To compare the mean differences between baseline and 6th week concentrations of lipid 
profile among the three groups.  
 
4- To assess the correlation between the mean differences in total to HDL cholesterol ratio 
and total cholesterol on the one hand, and HDL cholesterol on the other, for each group. 
 
Related to potentially oxidant and antioxidant parameters: 
1- To compare the mean concentrations of malondialdehyde oxidized LDL, and total 
antioxidant capacity at baseline, between the three groups: conventional yoghurt, probiotic 
yoghurt, and control.  
 
2- To compare the mean concentrations of malondialdehyde, oxidized LDL, and total 
antioxidant capacity, within each group at each interval (at baseline, after 3 weeks and after 
6 weeks).  
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3- To compare the mean differences between baseline and 6th week concentration of 
malondialdehyde oxidized LDL, and total antioxidant capacity among the three groups.  
 
Related to dietary intake parameters:  
1- To compare the intakes of calorie, fat, cholesterol, saturated fatty acids, monounsaturated 
fatty acids, polyunsaturated fatty acids, dietary fiber, beta carotene, vitamin C, and E at 
baseline among the three groups; conventional yoghurt, probiotic yoghurt, and control.  
 
2- To compare the intakes of calorie, fat, cholesterol, saturated fatty acids, monounsaturated 
fatty acids, polyunsaturated fatty acids, dietary fiber, beta carotene, vitamin C, and E within 
each group at each interval (at baseline, after 3 weeks and after 6 weeks).  
 
3- To compare the mean differences between baseline and 6th week values of calorie, fat, 
cholesterol, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, 
dietary fiber, beta carotene, vitamin C, and E among the three groups. 
 
 Individual related parameters: 
1- To compare the body weight and body mass index at baseline among the three groups:  
probiotic yoghurt, conventional yoghurt, and control. 
 
2- To compare the body weight and body mass index within each group at each interval.  
 
Hypothesis:  
1- There are improvements in lipid profile parameters in probiotic and conventional 
yoghurt consuming groups compared to the control group. 
 
2- There is a decrease in malondialdehyde and oxidized LDL concentration and 
increase in total antioxidant capacity in the probiotic and conventional yoghurt 
consuming groups compared to the control group. 
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3   LITERATURE REVIEW 
3-1  Probiotics  
 
3-1-1  Probiotic definition  
The term probiotics denotes “for life” and refers to microorganisms which have positive 
effects on human health. Micro-organisms presiding in food, especially lactic acid bacteria 
were believed to have beneficial health advantages from long ago. Abraham’s longevity, as 
asserted in the Old Testament (Persian edition), was due to the sour milk he drank. The 
Roman historian, Plinius, treated gastroenteritis with the help of milk products that were 
fermented. This dates back to 76 BC (Schrezenmeir and de Vrese, 2001).  
 
Since the introduction of the science of microbiology, researchers, including Tisser and 
Metchnikoff, have related these benefits to changes in microbial balance of the intestine 
(Tisser, 1984). The father of modern immunology, Metchnikoff, suggested that the 
consumption of milk fermented with Lactobacillus delbrueckii caused the evident long life 
of the Balkan peasants. His argument was that these bacteria would grow faster than the 
other damaging bacteria and hence reduce or inhibit their harmful activity in the gastro 
intestinal tract. This, in turn, would enhance our health by decreasing the amount of toxins 
in the gut. Tisser believed that diarrhea in infants could be treated with bifidobacteria. He 
suggested that these bacteria would render the putrefactive bacteria, that cause diarrhea, 
ineffective (Sanders, 2003). 
 
The term “probiotics” was created around the 1960’s, but the concept had been around from 
the beginning of the 20th century. As years have gone by the meaning of this term has 
changed. However the definition given by the Joint Food and Agriculture 
Organization/World Health Organization Working Group in 2001, i.e.; “Probiotics are live 
microorganisms which when administered in adequate amounts confer a health benefit on 
the host” seems to be the most accurate.  
The probiotic bacteria selected should have the following main characteristics: 
(Krishnakumar, 20001) 
• They should have “non-pathogenic’ activity 
• They should be “resistant to bile salts” and gastric acids 
• They should have the “desired technological and organoleptic properties” 
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• They should have “biological efficiency” on humans, including ‘adhesion to 
epithelial cells’ in the intestine 
• They should interact with “enteropathogenic” bacteria 
• They should be able to “colonize” in the gut 
• They should be able to “stimulate the immune system”. 
 
3-1-2  Important aspects of probiotics 
Viability    
On the definition of the term, even though many scientists insist on the viability of the 
microorganisms used as probiotics, several studies have shown that non-viable probiotics, 
too, can attach to the intestinal wall and reduce duration of diarrheal diseases (Conconier et 
al, 1993; Guarner et al, 2005). Studies examining probiotics’ immunological attributes have 
indicated that when living cells were given to patients, it led to a considerable increase in 
the number of cells that secrete IgA. The viability of the probiotic cells is essential for the 
probiotic antigens to be taken up through the Peyer’s patch, and also to adhere to the M-
cells within the intestine (Isolauri, 1999; Guandalini et al, 2000; Szajewskaey et al, 2007). 
Halpern et al (Halpern et al, 1991) showed in their study that consumption of yoghurt with 
living cells resulted in T-cells producing higher amounts of gamma-interferon. 
 
Survival within the GI tract                
In order for probiotics to have beneficial health effects, they must be able to travel through 
the upper gastro-intestinal (GI) tract intact. They must pass through the GI safely so as to 
reach the location they are to colonize. In order for the colonization to happen, probiotic 
must adhere to intestine’s epithelial and mucosal cells. This affects the length of time the 
bacteria stays within the intestine.  Also, it has an impact on the functional performance of 
the bacteria. The bacteria are strained by a number of stress factors while moving forward in 
the intestine. One such factor is the extremely low acidity (pH 1.5-3) of the stomach. The 
lowest acidity in which LAB can survive is 3.0, considerably higher than the acidity in 
stomach (Olejnik et al, 2005). 
 
The extremely high pH environment in the stomach is a crucial parameter in choosing LAB 
strains.  This harsh condition has a powerful impact on the viability of bacteria in the 
stomach. Olejnik et al. and Lee and Wong demonstrated that yoghurt’s pH reduced viable L. 
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casei cells, for 13 days, by 2 log-cycles, and when the pH reached 6.5, more than 30 days. 
These figures were 3 and 30 days at pH 4 and 6.6, respectively, for L.acidophilus CH5.  
Furthermore, B. bifida which is vulnerable to acidity, viable cells reduced after 4 and 15 
days at pH4.3 and 6.6.  Bacteria that are entered in the stomach stay there for 1 to 4 hours at 
pH less than 3.0 (Olejnik, 2005; Lee and Wong, 1998). That is long enough to kill most of 
bacteria. 
 
Pepsin is the next important parameter that has an impact on the bacteria. Various proteins 
that are involved in adhesion and aggregation activities, like binding mucus and collagen, 
are in the bacterial cell walls.  It is able to hydrolyze these proteins. This can have an impact 
on adhesive characteristics of bacteria and the integrity of cytoplasm membrane. Other 
lipolytic and proteolytic enzymes produced in small intestine can adversely affect survival 
of the bacteria.  Conjugated bile salts, too, have a devastating effect on the bacteria. They 
can ruin plasmatic membrane’s structure through emulsification. These greatly reduce the 
adhesive properties and the viability of the bacteria as they move through the gastro-
intestinal tract. 
 
Human origin  
There is disagreement on whether the probiotics used should be of human origin. But, as 
long as  it can be demonstrated that they can stay alive while passing through the GI tract, 
especially through the harsh stomach environment with induction of new genes encoding a 
number of stress proteins, and as long as they can show to be able to colonize in the large 
intestine, this is not a matter for concern. (Ljungh and Wadström, 2006) 
 
Adhesion 
It has been suggested that probiotic bacteria’s attachment to the intestine’s wall and their 
colonization of the gastro-intestinal tract is a vital precondition for their survival and 
functioning. Strains of probiotic bacteria with adherent properties are likely to stay longer in 
the intestine. They, thus, have better chances for manifesting immunological and metabolic 
effects, compared to the strains with no adhesion properties. The bacteria’s adhesion 
property causes them to interact with the mucosal surface and makes contact with gut 
associated lymphoid tissue (GALT) possible. It also plays a role in intestinal and systemic 
immune effects. Only probiotics with adherent properties are believed to stabilize the 
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intestinal mucosal barrier and to be instrumental in inducing the immune effects. Adhesion 
may also administer routs of exclusion of harmful bacteria and keep them away from the 
epithelium.  Various strains of probiotic bacteria possess different adhesive properties. 
It could be suggested that powerful capability for adhesion may raise the risk of infection in 
the individual. Certain strains of probiotics which are poorly adhering in vivo or in vitro still 
can show positive effects in the hosts (Saarela et al, 2000).  
 
Safety   
Both public health officials and scientific authorities seek assurances that a probiotic 
product introduced to the market can deliver live strains of the bacteria in sufficient numbers 
to the large intestine so that it may provide the desired benefit for the consumers.  
The amount of probiotics found in different food products differs a great deal. It has been 
suggested that in order for probiotic bacteria to have their therapeutic effects, at least 108 
colony forming units (CFU) should be consumed daily (Lourens-Hattingh and Viljoen, 
2001). These elevated amounts are necessary, it has been argued, because it should make up 
for the probable decrease in the probiotic organisms as they pass through the GI tract. The 
growing public interest in dairy products containing probiotics has induced a number of 
food companies to introduce minimum standards for the concentration of probiotic strains in 
their products. These require a minimum of 106 - 107 cfu/ g- of L. acidophilus and/or 
Bifidobacteria in their dairy products (IDF, 1992; Shah, 2000). It is further recommended 
that at least 106 cfu/g of probiotic bacteria present in probiotic yoghurts at the time of sale 
(Kurmann and Rasic, 1991). 
  
Based on epidemiological data on the effect of probiotics on the safety of dairy products, 
there is no evidence that these microorganisms are involved with human infections 
(Saavedra et al, 2000; Rolfe, 2000). Nevertheless the likelihood of infections resulting from 
the use of probiotics remains, infections that cause different reactions to a specific strain in 
different individuals. There are reports on infections induced by lactic acid bacteria. The 
majority of cases, however, concern patients with serious disfunctional immune systems.  
One should also remember that during the last twenty years the taxonomy of several LABs 
has been rebuilt (Ouwehand et al, 2002). The application of modern multi-phased 
classification has resulted in the re-categorization of many probiotic strains. Over all, 
probiotics are deemed quite harmless.  Numerous products containing probiotics have been 
used conventionally over centuries and their safety has been verified. 
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Resistance to antibiotic is increasingly a common characteristic among micro-organisms. 
This is a result of widespread and unchecked consumption of antibiotics in both human and 
animals. This has resulted in great difficulties in treating and healing of infections. 
Resistance of bacteria to antibiotics can be inherent or it may be acquired. Inherent 
resistance can be looked at as a species trait and is an innately occurring property. Acquired 
resistance to antibiotics, however, is caused by genetic alterations. Getting alien DNA from 
other bacteria can also cause this resistance. 
 
Antibiotic resistance (by plasmid-linked), is unusual in lactobacilli   Nevertheless it does 
take place and its consequences as far as the safety of humans is concerned need to be noted. 
As transfer of genes that are resistant to antibiotics may occur between bacteria which are 
phylogenetically unrelated, specific strains that carry the transportable components that have 
resistance genes should not be utilized. This holds true for both human products as well as 
animals.In short, safety issues concerning probiotics cover the following attributes: (Saarela 
et al, 2000) 
1. Strains that have human origin are preferred over those with non-human origin 
2. They should be isolated from healthy human GI-tract. 
3. They should be non-pathogenic. 
4. They should not have a history of association with such diseases as GI-disorders 
or infective endocarditis. 
5. They should not deconjugate bile salts (this would be a negative trait in the small 
bowel). 
6. They should not convey antibiotic resistance genes which can be transmitted. 
 
Technological aspects of probiotics       
It is necessary that probiotic foods have good sensory properties and that they be safe to 
consume. They should also contain specific probiotic strains at an adequate level through 
the storage.  It must be possible to produce probiotic strains in industrial settings without 
losing their functionality during storage as cultures in frozen or freeze dried form (Saarela, 
2000). Only then can they be given to customers. Furthermore, probiotic strains should not 
produce off-flavours or textures in the foods into which they are incorporated. In order to 
ensure the quality of probiotic bacteria, the resources used for packaging and also the 
circumstances the products are stocked and stored assume great importance. 
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Most commercial cultures for  probiotic products come in highly concentrated form, and are 
meant for DVS (direct vet set) application. It is customary to utilize these afore-mentioned 
highly concentrated direct vet set cultures because of the challenges in production of micro-
organism in the location that manufacturing takes place. The DVS cultures usually come in 
two forms; freeze-dried cultures or highly concentrated frozen cultures. 
 
3-2  Lactic acid bacteria as probiotics     
It has been suggested that a number of Bifidobacterium sp, Lactobacillus species, 
Saccharomyces boulardii, and several other microbes be utilize as probiotics.  They are 
usually, chosen from bacteria that normally live in the human gastrointestinal system and 
cause no health risk. These bacteria are first purified. Then they are cultivated and 
concentrated in high dosages and preserved. Basically, they are provided in the following 
forms (Saarela, 2000): 
• They are added as a “condense culture” to milk products or food, at medium level, 
with a very low chance, or no chance at all for culture growth. 
• They are added to “milk-based product” or supplement through inoculation and 
grow until they reach adequate levels in a fermented food.  
• They are provided as “condensed and dried cells packaged” in form of dietary 
supplements such as tablets, capsules, and powders. 
As probiotics, lactic acid bacteria have been associated with milk products for a long time. 
The reason is that a number of the same strains which are found in dairy products also reside 
in different parts of our body, such as the vagina, the mouth, the stomach, and the 
gastrointestinal tract. Some of these bacteria, therefore, can be used as a vehicle for 
transforming milk into a variety of dairy products which are fermented (cheese, yoghurt, 
kefir, etc.). They can also play the additional role of contributing to the process of 
colonizing bacteria. Fermented milk products can, therefore, be a suitable medium to 
provide probiotic. 
Probiotic bacteria are not identical. They are different in their gene make up, species and 
strain. Strains of the same species may differ in traits and attributes. Such attributes consist 
of type and extent of inhibitors they create, stability, manifestation of enzymes, forms of 
carbohydrate fermentation, their ability to produce acids, their non acceptance of bile and 
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acids, their capability to inhibit the GI tract. Also perhaps the most significant attribute is 
the strains proven clinical ability to produce desired effects (Sanders, 2000).  
Various yeasts and bacteria used as probiotics, including:  
- Lactobacillus 
- Bifidobacterium   
- Lactococcus  
- Saccharomyces (yeast) 
- Streptococcus Thermophilus  
- Enterococcus 
 
3-2-1  Lactobacillus 
Lactobacillus is gram-positive bacteria. They are able to function in the presence or absent 
of oxygen. Lactobacilli are an important part of the LAB bacteria. They are called by this 
name because the majority of them are able to change lactose and other simple carbohydrate 
to lactic acid. Lactobacilli normally live in the human intestine and vagina. They are usually 
live in vagina or GI tract in the human body. They are considered as a major species of the 
gut flora (Olejnik et al, 2005).  Some Lactobacilli used as probiotics include: 
 
Lactobacillus acidophilus 
Lactobacillus casei 
Lactobacillus crispatus 
Lactobacillus bulgaricus  
Lactobacillus curvatus 
Lactobacillus brevis 
Lactobacillus plantarum 
Lactobacillus rhamnosus 
Lactobacillus GG 
Lactobacillus cellobiosus 
Lactobacillus fermentum 
Lactobacillus gasseri 
Lactobacillus johnsonii 
Lactobacillus salivarus 
Lactobacillus acidophilus BG2FO4 
Lactobacillus johnsonii LA1 
Lactobacillus acidophilus NCFM 
Lactobacillus acidophilus INT-9 
Lactobacillus plantarum ST31 
Lactobacillus reuteri 
Lactobacillus casei Shirota 
Lactobacillus acidophilus DDS-1 
Lactobacillus acidophilus NCFB 1748 
Lactobacillus delbrueckii 
Lactobacillus salivarius UCC 118 
Lactobacillus acidophilus SBT-2062 
Lactobacillus paracasei 
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3-2-2  Bifidobacterium  
Bifidobacteria normally live in the human and animal GI tract. In less than a few days after 
birth, infants are colonized with these bacteria for the first time Bifidobacteria was isolated 
from breast-fed baby’s feces. They are gram positive and usually have a Y form. The 
number of these bacteria is relatively constant in early stage of life, but later it decreases as a 
result of drugs such as antibiotics, and because of changes in the diet. They are able to 
generate lactic acid without making carbon dioxide. They are also categorized as LAB 
bacteria.  Some Bifidobacteria applied as probiotics include: 
 
Bifidobacterium adolescentis 
Bifidobacterium infantis 
Bifidobacterium breve 
Bifidobacterium animalis 
Bifidobacterium longum  
Bifidobacterium bifidum 
Bifidobacterium thermophilum 
Bifidobacterium lactis 
Bifidobacterium breve  
 
  
 Bifidobacterium longum BB536 
 Bifidobacterium infantis RO33 
 Bifidobacterium breve RO7O 
 Bifidobacterium bifidum RO71 
 Bifidobacterium lactis Bb12 
 Bifidobacterium longum RO23 
 Bifidobacterium longum SBT-2928 
 
 
 
 
3-2-3  Lactococcus  
Lactococci are also gram-positive bacteria which can function with or without oxygen.   
Also they are considered as part of the family of lactic acid bacteria. Lactococcus lactis (or 
streptococcus lactis) can be found in milk-based products. Souring of milk is a result of 
Lactococci bacteria activity. Lactococci that are used as probiotics include:  
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Lactococcus lactis, subspecies cremoris 
Lactococcus lactis, subspecies lactis NIAI 1061 
Lactococcus lactis, subspecies lactis NIAI 527 
Lactococcus lactis, subspecies lactis NCDO 712  
Lactococcus lactis, subspecies lactis biovar diacetylactis ATCC 13675 
Lactococcus lactis, subspecies lactis biovar diacetylactis NIAI 8 W  
 
 
 
3-2-4  Saccharomyces  
Saccharomyces is categorized as yeast. Saccharomyces boulardii is the main probiotic 
yeast. S. boulardii is usually not pathogenic yeast. It is administered in treatment of 
antibiotic induced diarrhea. 
 
3-2-5  Streptococcus Thermophilus  
Streptococcus thermophilus, is a gram-positive bacterium that is able to function 
anaerobically and aerobically. It is a catalase-negative, homofermentative, and non-motile 
bacteria. It, too, is considered as a member of lactic acid bacteria family. Streptococcus 
thermophilus can be found in milk and milk-based products. It is a one of the main strains 
needed for production of yoghurt. Another probiotic strain is Streptococcus salivarus 
subspecies thermophilus type 1131. 
 
3-2-6  Enterococcus  
Enterococci are also among gram-positive bacteria. They are facultative anaerobics so can 
function anaerobically and aerobically and are catalase-negative. They are generally not 
motile, and non-spore forming. Enterococci reside in the intestine and are part of the normal 
flora of humans and animals. A probiotic strain of these bacteria is Enterococcus faecium 
SF68, which has shown to be effective in diarrheal diseases.  
 
3-3  Probiotics - mechanisms of action 
Probiotic bacteria benefit human being in a variety of manners. Releasing antimicrobial 
substances in the body, resisting colonization of harmful bacteria, stopping pathogens from 
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attaching to GI tract, breaking up destructive elements, enhancing the immune system, 
boosting the activity of brush border enzymes, are among probiotics’ actions that affect our 
health and wellbeing (Isolauri et al, 2001; Walker, 2000; Ruemmele et al, 2009; Isolauri and 
Salminen, 2008; Salminen et al, 2006; Zhang et al, 2005).  
 
Most probiotic agents can generate compound with antimicrobial properties (Organic acids, 
hydrogen peroxide, and bacteriocins) that are able to decrease pathogens in a direct manner 
or work indirectly by changing their metabolism and prevent endotoxin activity (Ingrassia et 
al, 2005; Candela, 2008).  In order to understand how probiotic bacteria operate, one has to 
have a good insight of the microbiology and physiology of the gastrointestinal tract.   
 
3-3-1  The gut microflora 
The human gastrointestinal tract is eight meters long and has a surface area the size of a 
football field. From amongst all the organs in the body the GI tract has the most interaction 
with the environment. Thus, its role is to ingest and absorb nutrients. It is also in charge of 
the emission of waste products. As the largest organ that is involved in the functioning of 
our immune system, it creates 80% of the antibody in our body. Of the 100 billion bacterial 
cells (1 kg bacteria) within the intestinal microflora, many are useful while others can be 
harmful. Some are capable of being both, while the function of others is uncertain. 
 
Human GI tract is sterile until birth, when microflora are introduced to it through mother’s 
vagina and feces. The colon population in babies that take milk directly from mother’s 
breast consists of 90% bifidobacteria, as well as certain amounts of enterobacteriaceae and 
enterococci. However, there are almost no staphylococci, bacteroides, clostridia, or 
lactobacilli present. These microfloras are important for formation and development of the 
immune function of the gut, both in the post-natal period and also for its development in the 
first years after birth.   From approximately the age of three the composition of the flora 
becomes extremely complicated. This will last all the way to the age of maturity.  The 
equilibrium of the miroflora plays a vital role in the preservation of the intestine and 
definitely in preserving the body throughout life. The bacteria colony varies depending on 
the location. This is because of the various environments within the tract.  The number and 
type of the indigenous microflora varies in different parts of the GI tract (Gionchetti et al, 
2000). For example, since the acidity level is not suitable for bacteria, there is only minor 
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colonization in the stomach. This is also the case for the upper section of the small intestine. 
In the lower section of the small intestine the number of bacteria is high and in the colon it 
is even higher. In the upper intestine, the bacteria count is below105 (cfu) per ml of content. 
This indicates comparatively light density of flora. In the mid ileum, there is a rise in the 
bacteria count, reaching 107cfu per ml of contents. This points to an alteration in density, 
moving towards the thick flora present in the colon (de Vrese and Schrezenmeir, 2008). 
 
The symbiosis in which the microflora of the intestine live in is complex and fragile. As 
long as their balance is maintained, the bacteria that have the potential to be harmful are 
contained. On the other hand, many factors in life, like inappropriate diet, antibiotic 
treatment, harmful bacteria, and surgery can disrupt this state of equilibrium. Other factors 
which can contribute to the disruption of this balance are too much travel, illness, and 
growing old.  Whenever this state of equilibrium is upset within the intestine, the harmful 
bacteria find a chance to thrive and multiply. The growth of these bacteria causes digestive 
ailments and illnesses.   
 
 
3-3-2  The gut immune system 
Probiotics modulate both the GI tract’s microflora and the immune system (Gorbach, 2000; 
Isolauri et al, 2000; Viljanen et al, 2005). The intestine functions as an extended mucosal 
surface, where the “interior” of the body comes into contact with the outside. It is along this 
important interface that alien microorganisms and antigens that take up residence or pass 
through the GI tract come into contact with body’s vital immune system.  Working against 
this ‘colonization’ of foreign elements is a fundamental activity of the intestinal flora. As 
soon as a foreign microorganism attaches to the intestinal surface, the epithelial layer acting 
as a very important obstacle against invasion stops these bacteria from merging with the 
eukaryotics cells present in the host (Walker, 2000; Walker, 2008). 
  
It is essential that this obstacle structure remain healthy and functioning for the health of the 
individual. Malfunction and disease result when there is an alteration in the composition of 
the microflora of the gut or in the GI barrier. Microbes that normally live in the 
gastrointestinal tract strengthen this important role as well by preventing the foreign 
microorganisms and antigens from passing through the intestinal wall into blood circulation.  
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It is suggested that it reduces infections and perhaps reactions to antigens (Hooper and 
Gordon, 2001). It is in this intricate scheme of cooperation that the fine balance between the 
microflora and the gastrointestinal tract is sustained.  
 
The immune and protective defense of the human GI tract includes the following 
components in the gut: 
• Immune system: It acts through a complex set of mechanisms generating certain 
WBC that create antibodies to take on the foreign harmful microorganisms.  
• Mucosa and epithelium: They act as a physical blockage and sustain the intestinal 
permeability balanced. At the same time, they stop the harmful bacteria from 
attaching to the intestine’s wall.  
• Microflora: Its role is to guard the body against harmful microorganisms  
 
The high metabolic activity of the microbiota in the intestine is another function important 
to the host.  Reduction in the acidity of the gut creates a harsh milieu for pathogenic 
bacteria.   This in turn helps the good bacteria in their resistance against harmful organisms, 
as mentioned above 
 
These bacteria are further able to produce antimicrobial compounds (such as peroxide, 
bacteriocins, and SCFA) that stop pathogens. The beneficial bacteria release SCFA, on 
which the immune cells also rely.  Acetate, propionate and butyrate are three types of 
SCFAs that are produced as a result of fermentation activity by the bacteria. Butyric acid is 
viewed as one of the most significant substances derived from this process. The reason for 
this is that this acid is an ideal source of energy for epithelial cells. It is believed that butyric 
acid has an important responsibility in lowering the chances of getting colon cancer.  Within 
the colonic lumen, clustering of short chain fatty acids aids in preserving a suitable pH. This 
is vital for effectiveness of numerous enzymes and for inhibiting metabolism of harmful or 
cancer causing agents in the gut (Candela et al, 2008). The role of the mucous in the 
intestine is to shield the epithelium, thus stopping enzymes, acid and bile from inflicting 
harm.   
 
The intestinal epithelium is an added obstacle that protects it against the attack of 
microorganisms and foreign elements. As the location where all sorts of immunocompetent 
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cells function, the intestinal mucosa has a vital role in the human immune system. Nearly 80 
percent of all cells which produce immunoglobulin in the body are produced by the gut-
associated lymphoid tissue (GALT) (Dubois et al, 2005; Granger et al, 2006).  Peyer’s 
patches in the intestine are specialized to gather antigens from the epithelium in the GI tract. 
They render them to the immune system and trigger a defensive reaction.  Interactions 
between useful bacteria or their metabolic products and the GALT in the bowel stimulates it 
(MacDonald and Gordon, 2005; Ouwehand et al, 2002). Research done on animals that were 
reared under sterile conditions has shed light on the significance of the intestinal microbiota 
in the growth of the gastrointestinal tract and its role in our bodies’ defense mechanism 
against harmful microorganisms and pathogens.  
 
A number of probiotic strains are capable to stimulate local and peripheral immunity. 
Lactobacilli are able to enhance both cellular and humoral immunity through phagocytes, 
macrophages, neutrophils, NK cells, and monocytes. (Vanderhoof, 2001). 
 
L. casei has shown the capability to stimulate immune system and to increase phagocytic 
activity (Nagao et al, 2000; Maassen et al, 2000). In addition S. boulardii has demonstrated 
the ability to induce the immune system and stimulate activity of neutrophils, leukocytes, 
complement component (Guslandi et al, 2000). L. casei has shown ability to improve IgA 
response in Crohn’s diseas (Gupta et al, 2000). 
 
 
 
 
3-4  Some potential health benefits of probiotics  
There are a variety of proposed beneficial health effects of probiotics. Probiotics seem to be 
able to help in treatment of diarrhea, lactase intolerance, gastroenteritis, allergies in infants, 
hyperlipidemia, inflammatory bowel disease (IBS), irritable bowel syndrome (IBD), cancer, 
depressed immune function, Helicobacter pylori infections, and others. Some of the health 
benefits of probiotics will be discussed below. 
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Allergies/eczema - Over the last 35–40 years, the prevalence of allergic diseases has 
increased especially in Western countries. In babies, GI disorders are usually observed when 
symptoms of atopic eczema – that inhibits growth - are present. Research has mainly been 
done on how probiotics may affect allergies.  In fact, probiotics may have positive effects on 
allergies through enhancing mucosal role as a barrier and boosting stimulation of the 
immune system (MacFarlane and Cummings, 2002). Probiotics are effective in 
hypersensitivity related inflammation among patients allergic to certain foods and those 
with atopic eczema (Majamaa and Isolauri, 1997; Murch, 2001; Pohjavuori et al, 2004; 
Isolauri, 2004; McFarland, 2000). 
 
In newborn babies, the initial bacteria to colonize the sterile gastrointestinal tract may cause 
a permanent niche there. They will have continuing effect on immune regulation and later 
development of atopic disorders. Administration of lactobacillus rhamnosus GG before 
birth has demonstrated a reduction by 50 percent in subsequent incidence of eczema in 
infants that are at risk (Isolauri et al, 2000). The health of infants with eczema notably 
improved when they were fed Lactobacillus GG-fortified hydrolyzed whey formula for a 
month. This was an indication of probiotics’ ability to stimulate the gut’s own barrier 
function that would reduce inflammation in the intestine and curing food induced allergy 
(MacFarlane and Cummings 2002; Kalliomaki and Isolauri 2004; Del Miraglia and De Luca 
2004).  
 
Probiotic bacteria may further be able to have a role in alleviating allergy symptoms caused 
by proteins in milk. The positive effect of probiotics in the above mentioned case may be 
due to breaking down milk proteins into smaller amino acids and peptides, thereby 
alleviating atopic dermatitis symptoms (Majamaa and Isolauri, 1997). Probiotic bacteria 
have further demonstrated the ability to upregulate anti-inflammatory cytokines, such as Il-
10, in children with atopic eczema (Pessi et al, 2000). Other researches on animals and 
humans have demonstrated these bacteria’s favorable effect on the immune system 
(Savilahti et al, 2008).  
  
 
Diarrhea - A number of studies have shown that when patients suffering from acute 
diarrheal disorders, such as traveler’s diarrhea, rotavirus infection, diarrhea related to 
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Crohn’s disease and AIDS, and other severe bacterial infections such as Clostridium difficile 
are treated with probiotics, there is improvement in their condition (Gionchetti et al, 2000; 
Vanderhoof, 2001; Szajewska et al, 2001). Significantly, studies in which saccharomyces 
boulardii or lactobacillus species were given to patients, showed a decrease repeated 
episode of Clostridium difficile-induced diarrhea (Schultz and Sartor, 2000). 
 
Clinical studies have shown that certain bacteria strains such as bifidobacteria spp., 
lactobacillus reuteri, lactobacillus GG, are very effective in alleviation of diarrhea 
symptoms (Benchimol and Mack, 2004). Lactic acid bacteria are able to release a variety of 
enzymes into the GI tract that have synergistic effects on ingestion, and reducing symptoms 
of intestinal disorders (Gionchetti et al, 2000; Levy, 2000; Saavedra, 2000; Marteau et al, 
2001). 
 
Probiotic therapy has shown positive results in treatment of rotavirus infection and in 
reducing the length of acute phase of the diarrhea among children suffering from the disease 
(Solga, 2003; Tomas et al, 2004).   
 
Probiotics, by their presence on the epithelial cells, may hinder activities of harmful bacteria 
and viruses or, by releasing bacteriocins like nisin, may prevent their growth (Del Miraglia 
and De Luca 2004). Also, probiotics fight the harmful bacteria over binding sites (Saulnier 
et al, 2009). In addition, administering probiotics can enhance the immune system.  
 
Irritable Bowel Syndrome (IBS) -  Studies have demonstrated that probiotic bacteria can be 
helpful in treatment of functional and inflammatory bowel disorders Normal gut physiology 
is shaped by the interaction between the intestine’s microbiota and the host’s gastrointestinal 
tissues. This includes secretion, absorption, motility, and permeability (Verdu and Collins 
2004). In clinical studies on IBS, an common disorder, L. plantarum 299v and DSM 9843 
strains were demonstrated to reduce symptoms such as bloating, abdominal pain, 
constipation, and flatulence (Steidler et al, 2000; MacFarlane and Cummings 2002). It has 
been reported, though Sacc. boulardii was able to reduce diarrhea in IBS, was not helpful in 
reducing the symptoms  (Marteau et al, 2001). 
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Helicobacter pylori infections - Unlike other microbes, a few lactobacillus strains are able 
to stand low acidity and stay alive and flourish under the harsh conditions in the stomach. 
This may provide a chance to eliminate the excess growth of Helicobacter pylori, and 
prevent conditions such as peptic ulcers and chronic gastritis.  Aiba et al (Aiba et al, 1998) 
demonstrated that Lactobacillus salivarius can prevent Helicobacter pylori growth by 
making lactic acid in excessive quantity. There are contradictory results on administration of 
probiotics to Helicobacter infected patients (Franceschi et al, 2007; Ryan et al, 2008).  
Administration of probiotics food over an extended period of time may reduce acute GI 
inflammation and hence be effective in the treatment of the infection. 
 
 
Alleviation of lactose intolerance - Alleviation of lactose intolerance – People with β-
galactosidase (lactase) deficiency cannot tolerate milk and dairy products, except yoghurt. 
The fact that these individuals can tolerate fermented milk is believed to be due to the LAB 
present in the yoghurt that stimulates lactase activity in the small intestine (De Vrese and 
Schrezenmeir, 2008). 
 
 
HIV and immune function – In vitro and in vivo studies on animal and human systems 
have indicated that probiotic bacteria, by increasing cytokines and immunoglobulin 
productions and by activating natural killer cell and macrophages, can improve nonspecific 
and specific immune responses (Perdigon and Alvarez 1992; Ouwehand et al, 2002).   
 
Some LAB may be helpful in managing AIDS symptoms. L. plantarum 299v have shown to 
improve the immune system and individuals whose immune systems have been damaged, 
have benefitted from it. Feeding the bacteria to children with HIV who suffer from 
occasional diarrhea and malabsorption due to excess growth of bacteria, has shown 
promising results (Cunningham-Rundles et al, 2000; Trois et al, 2008).  
 
Disseminated systemic “Candida albicans” were reduced by bifidobacteria and 
lactobacillus spp. bifidobacteria in the “immunodeficient euthymic mouse model” (Wagner 
et al, 1997). Consumption of products containing probiotics by patients whose immune 
systems have been compromised looks promising. However, as few tests are done on human 
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immune function, one should not draw conclusions on the effects of probiotic bacteria on 
humans, especially those with compromised immune systems (Ledoux et al, 2006).  
 
Urogenital Infections - Some studies show the potential effects of probiotic strains of some 
lactobacilli in treatment of urogenital infections, such as bacterial vaginosis and urinary 
tract infections (Hoesl and Altwein, 2005; Falagas et al, 2006). 
 
Hyperlipidemia - Another hitherto unknown benefit of probiotics is its ability to reduce 
serum lipid. Accumulating evidence suggests that probiotic bacteria may have a positive 
effect on the level of lipids in blood. It was thought that the probiotics’ effect on cholesterol 
assimilation was “strain-dependent”. Since in vitro studies demonstrated certain bacteria 
could take out cholesterol from culture media (Gilliland and Walker 1989; Lin and Chen, 
2000; Parvez et al, 2005). Other studies have focused on the cholesterol-lowering ability of 
probiotics in humans (Tamime, 2002).  
 
This may have important implications in prevention of cholesterol reabsorption back into 
systemic circulation. Studies ranging from in vitro to animals to humans have produced 
mixed results. One of the main goals of this study is to assess the effects of probiotic 
yoghurt on lipid profile. In the following section the effects of probiotics on serum lipids 
will be reviewed in depth. 
 
 
3-5  Effects of probiotics on plasma lipids 
The idea about the health advantages of fermented milk products in humans go back to the 
early 19th century. Then, Metchnikov proposed that fermenting milks by lactic acid bacteria 
"prevented intestinal putrefaction" and "helped maintain the forces of the body" (St-Onge, 
2000). A study on Maasai tribesmen in Africa who have low serum cholesterol showed that 
they rarely experience coronary heart diseases, despite eating a great deal of meat. They 
regularly consumed 4-5 liters of fermented whole milk per day. This provided the 
motivation for investigating fermented milk’s possible influence on blood cholesterol (Mann 
and Spoerry, 1974).  
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Later, in a study by Mann (Mann, 1977), on twenty-six volunteers, it was found that large 
amount of yoghurt reduced cholesteroemia, which could be due to a factor in yoghurt that 
prevents production of cholesterol from acetate. This factor may be either orotic acid or 3-
hydroxy-3- methylglutaric acid plus thermophilus milk or methanol soluble of thermophilus 
milk. 
 
 
3-5-1  In vitro and animal studies 
Gilliland et al. showed that two strains of lactobacillus acidophilus (removed from swine) 
were able to grow while bile was present (Gilliland et al, 1985). One of them utilized 
cholesterol from culture media under anaerobic conditions and considerably hindered any 
upward movement in serum cholesterol in pigs on high-cholesterol diet. The second bacteria 
did not show any effect on cholesterol in culture media or in the pigs.  The researchers’ 
conclusion was that these bacteria make it possible for cholesterol to be bound to intestine’s 
lumen and as a result decrease its absorption. Lactose, casein, orotic acid, and 
hydroxymethyl glutaric acid are believed to have hypocholesterolemic effect. 
 
Tahri et al.  (Tahri et al, 1996) investigated assimilation of cholesterol by “B.  longum, B. 
infantis, B. breve, B. animalis and B. thermophyllum” in the presence of bile salts and 
observed that the removal of cholesterol from the growth medium by bifidobacteria strains 
is caused by both bacterial activity  and precipitation of cholesterol.  
 
Lin and Chen (Lin and Chen, 2000) investigated cholesterol-reducing abilities of six strains 
of L. acidophilus and found that in vivo hypocholesterolaemic ability is probably because of 
the assimilation of cholesterol by L. acidophilus cells  or its attachment to the surface of L. 
acidophilus cells .  
 
Grunewald (Grunewald, 1982) conducted an experiment, where rats were fed with 
fermented milk, to study the growth response and lipid profiles. Rats were divided into three 
groups: water (control); water plus 10% milk, and water plus 10% fermented milk. 
Fermented milk was prepared with probiotic strain L. acidophilus. Though the results were 
non-significant, there was a strong reduction in serum cholesterol of fermented milk-fed 
rats, indicating that cholesterol level in serum can be reduced by consumption of probiotics.  
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In another investigation, rat chow plus water, milk, or skim milk, and milk enriched with S. 
thermophilus was given to rats for 29 days (Rao et al, 1981). Plasma cholesterol 
concentrations were significantly higher in the group that was fed water or skim milk as 
compared to the thermophilus milk. The study further suggested that orotate metabolites that 
were created in the fermentation process in S. thermophilus–fermented milk could cause 
reduction in cholesterol concentration.  
 
It was also seen that yoghurt decreased hypercholesterolemia that had resulted from high 
cholesterol in food given to rabbits (Kumar and Christopher, 1989). Their serum cholesterol 
elevation showed a 90% decrease in rise when L. sporogenes were administered to them. It 
was shown in in-vitro studies that L. sporogenes utilized cholesterol from the culture 
medium. This means that it may be able to use cholesterol directly from the GI tract (Kumar 
and Christopher, 1989). 
 
A different study conducted on mice with high cholesterol demonstrated that L. reuteri was 
able to reduce blood lipid. Low levels of the bacteria given to the mice for a week reduced 
their triglyceride by 38% and their cholesterol by 40%. It also raised their HDL/LDL 
cholesterol ratio by 20% (Taranto et al, 1998). 
 
Non-fat milk fermented with L. casei shirota was given to Syrian hamsters for 2 weeks. It 
caused a reduction in triglyceride level in hamsters that were given a diet with no 
cholesterol and also in those fed a high cholesterol diet, compared to control group 
(Kikuchi-Hayakawa et al, 2000). 
 
Xiao et al examined the effects of probiotic enriched milk products on blood lipids in rats 
(Xiao et al, 2003). They used fermented milk contained bifidobacterium longum strain BL1. 
Rats were given cholesterol-enriched food. Their diet was enriched with lyophilized milk 
powders, as follows: 1)- acid milk, 2)- milk fermented with a culture of normal yoghurt 
made up of thermophilus, streptococcus, and lactobacillus delbrueckii subsp. Bulgaricus, 
and 3) bifidobacterium milk fermented with B. Longum strain BL1.  In rats, consumption of 
bifidobacterium milk led to a meaningful reduction in their triglyceride, low density lipid, 
and total cholesterol, compared to the control group. The group that was fed ordinary 
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fermented milk, their HDL cholesterol level remained unchanged. This group showed a 
minor drop in its lipid levels. 
 
Abd El-Gawad et al in a study placed rats on a high cholesterol diet for six weeks (Abd El-
Gawad et al, 2005). They were fed yoghurt and soy-yoghurt containing B. lactis Bb-12, or B 
longum Bb-46. The groups which were given B. lactis Bb-12 showed much lower 
cholesterol in their plasma and liver than did the group on cholesterol diet alone.  Bb-46 
demonstrated to have more cholesterol-lowering effect than Bb-12. This underlines the 
significant differences among the various bacteria strains.  
 
 
 
3-5-2  Human studies 
Studies, on effects of fermented dairy products on human cholesterol have begun in the 
1970s. Hepner et al (Hepner et al, 1979) investigated the result of consumption of yoghurt 
on plasma lipid level in humans. In order to uncover the effect milk products had on serum 
triglycerides and cholesterol, 54 subjects were studied for different durations, during which 
they were given dietary supplementation of non-pasteurized yoghurt, pasteurized yoghurt 
and 2% butterfat milk. After consumption of either non-pasteurized or pasteurized yoghurt 
for one week there was a significant reduction in serum cholesterol by 5 to 10 percent.  
However decrease in cholesterol was less significant in butter milk consuming group.  
 
Lin et al (Lin et al, 1989) conducted two studies. One was a pilot study with no placebo, and 
the other was a large placebo-controlled study. In the first one, twenty-three participants 
were given tablets that contained (3 × 107 CFU) L. bulgaricus and L. acidophilus for 16 
weeks every day, while fifteen participants were given none.  Blood cholesterol was reduced 
significantly in the experimental group. A second study – placebo controlled, double blind, 
with a crossover design – was conducted. No significant change in blood cholesterol was 
seen.   
 
In another study hyperlipidemic patients that were given lactobacillus sporogenes for 90 
days, showed a 35% and 32% decrease in their LDL and total cholesterol levels, 
respectively (Mohan, 1990).  
 
 27  
In a randomized, double blind, placebo controlled trial, a milk product (Gaio), fermented 
with two strains of S. thermophilus and Enterococcum faecium, and was examined for its 
effects on lowering cholesterol (Agerbaeck et al, 1995).  Healthy men with normal serum 
cholesterol levels were told to add 200 ml/day of FM to their usual diet over a six-week 
period. The placebo group consumed milk acidified with an organic acid. In the fermented 
milk consuming group, there was a significant decrease in total cholesterol of 3% and 6% 
after 3 and 6 week of administering the product, respectively, and LDL cholesterol levels 
decreased by 10% after 6 week of consumption.  
 
Two controlled clinical trials were conducted to study the effects of eating a single daily 
serving (200 ml) of fermented milk containing lactobacillus acidophilus L1 taken from 
humans or fermented milk with L. acidophilus ATCC43211 from swine on lipids (Anderson 
and Gilliland, 1999). The first study was single-blind and lasted for 21 days.  The result of 
first trial showed a significant (2.4%) decrease in blood cholesterol for FM containing 
lactobacillus acidophilus L1. The second part was a placebo-controlled, double-blinded, 
cross-over study. In the second part of the study subjects consumed either fermented milk or 
FM containing L. acidophilus L1 over 4 weeks. In the second trial, L. acidophilus L1caused 
a 3.2% (P<0.05) decrease in blood cholesterol during the first interval. In the second 
interval, cholesterol remained unchanged. Collective analysis of the two L1 treatment trials 
revealed 2.9% reduction in blood cholesterol level (Anderson JW, Gilliland SE. 1999). 
 
In a randomized, 2-month, double-blind clinical study, effects of fermented yoghurt on 
serum cholesterol of overweight individuals was examined. They consumed 450 ml/day 
yoghurt fermented with Strep. thermophilus and E. faecium. Results showed an 8.4% 
decrease in low density lipid cholesterol and an increase in fibrinogen concentrations 
(Agerholm-Larsen et al, 2000).  
 
In a randomized clinical trial, 32 subjects with serum cholesterol 220-280 mg/dl were 
recruited. After a four-week consumption of 300 ml/day ordinary yoghurt or ordinary 
yoghurt starters plus Bifidobacterium longum strain BL1, sixteen of the participants in the 
probiotic group showed a decrease in their total cholesterol. Participants with relatively high 
total cholesterol (> 240 mg/dl) showed a particularly significant reduction in their blood 
lipid. Serum cholesterol levels in the rest of the probiotic group remained almost stable 
during the experiment (Xiao et al, 2003). 
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In a randomized, 56-week, double blind, placebo controlled clinical trial, the effect of 
enterococcus faecium, enriched with selenium on plasma lipids was studied (Hilvak et al, 
2005). The result demonstrated that E. faecium M-74 probiotic strain reduced cholesterol 
levels by 12%. As high density lipid and triglyceride concentrations showed no significant 
change, the decrease in serum cholesterol must be mainly attributed to a drop in low density 
lipid cholesterol.  
 
 
In a cross-over clinical trial the effects of probiotic and conventional yoghurt on serum 
lipids of women with normal cholesterol concentrations were studied (Fabian and Elmadfa, 
2006). Volunteers were given 100g/day of probiotic enriched yoghurt (L. case) or 
conventional yoghurt for 14 days and, without a washout period, another two weeks of 
200g/day. A number of lipid levels were affected in both the conventional and the probiotic 
yoghurt groups, but no meaningful difference was seen between the two.  
 
 
Twenty-six volunteers were recruited for a placebo-controlled, double-blind, randomized 
crossover study (Klein et al, 2008). After a 21-day run-in period, thirteen of them were 
given 300 g/day of probiotic yoghurt with lactobacillus acidophilus 74-2 and 
bifidobacterium animalis subsp. lactis DGCC 420. The rest of the group was given placebo 
for five weeks. The two groups switched in the next five-week trial. Even though L. 
acidophilus and B. lactis were recovered in feces in significantly elevated number after 
supplementation, fecal SCFA and serum cholesterol levels were not changed. A significant 
reduction (11.6%) in serum triglyceride levels were observed, however, during the period 
probiotics were consumed.  
 
In a randomized, single-blind, placebo-controlled, parallel-arm trial, fifty-five individuals 
with normal cholesterol levels, eighteen to thirty six years of age  were selected (Greany et 
al, 2008). Volunteers was given either three probiotic capsules each containing 109 (cfu) 
lactobacillus acidophilus and bifidobacterium Longum and 10–15 mg fructo-
oligosaccharide,  or three placebo capsules per day for 60 days. The results showed no 
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change in plasma concentrations of triglyceride, HDL, LDL, and total cholesterol in any 
group.  
 
 
Summary 
In vitro experiments with bifidobacteria and lactic acid bacteria indicate some strains of 
these bacteria are able to assimilate cholesterol when bile is present. The capability of some 
strains to lower the level of cholesterol in humans needs to be verified in mixed substrate 
environments and cultures. Extensive studies done on animals and humans indicate that 
dairy product fermented with the right strains of LAB have cholesterol lowering activity. It 
is the bacterial content, according to most of these studies that produce this 
hypocholesterolemic ability.   
 
Furthermore, some studies have indicated that combinations of different bacterial strains are 
more effective in lowering cholesterol than a single type. The differing results obtained from 
in vivo studies on the effect of fermented milk and yoghurt on cholesterol can be explained, 
at least in part, by various strains that have been used. Another important factor in 
successful application of probiotics is their ability to survive in the gut and colonize in the 
small intestine. The fact that confounding factors are also active in the environment makes 
reaching a decisive conclusion so much more difficult.  
 
 
 
 
 
 
3-5-3  Mechanism of action 
Before discussing the probiotics’ mechanism of action on plasma lipids, a summary of 
lipoprotein synthesis and metabolism will be reviewed. 
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3-5-3-1   Plasma lipoprotein synthesis and metabolism 
 
Important organs in the body that are responsible for synthesis and transport of lipoprotein 
are the liver and the gut. A cystic duct brings bile from the gallbladder to the gut. The liver 
produces the bile, but it is moved to the gallbladder and remains there to be used. Once a 
fatty meal arrives at the small intestine, bile salts get into action and help with 
emulsification of the fats. This makes their digestion and absorption in the gut possible. 
Fatty acids, triglycerides, and cholesterol combine in the epithelial cells of the gut where 
they are covered with a layer of protein. These are called chylomicrons (Kaplan & Pesse, 
1996).  
 
The lymphatic system absorbs these chylomicrons and later releases them into the blood. 
Chylomicrons find their way to the liver and it turns them into triglyceride and cholesterol. 
Bile salts do not end up in the gut with the fats. They move down all the way to the ileum. 
There, most of the bile salts are absorbed once again and entered into the blood. The 
circulation takes the bile salts back to the liver. They remain in the gallbladder, with bile, to 
be used for the above process again. Some of the bile salts are not absorbed in the small 
intestine and end up in the colon and are disposed of with feces. The liver makes up for its 
lost of the bile salts by synthesizing them from its cholesterol reservoir.  
Cells in the liver also synthesizes cholesterol and are therefore another major source of the 
body’s cholesterol pool, in addition to the dietary sources of cholesterol. A number of 
factors, such as genes and diet, stimulate the liver to produce cholesterol. 
 
Biosynthesis of Cholesterol – Just under 50% of the body’s cholesterol comes from new 
biosynthesis, nearly 10% in the liver, and 15% in the intestine (Kaplan & Pesse, 1989). 
“Cholesterol synthesis occurs in the microsomes and cytoplasm from the two-carbon acetate 
group of acetyl-CoA” (Dessi and Batetta, 2003).  The biosynthesis of cholesterol goes 
through the following stages: 
1. “Conversion of Acetyl-CoAs to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA),  
2. Conversion of HMG-CoA to mevalonate,  
3. Changing of mevalonate to isopentenyl pyrophosphate,  
4. Changing of isopentenyl pyrophosphate to squalene,  
5. Conversion of squalene to cholesterol.”  (Dessi and Batetta, 2003) 
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Regulating Cholesterol Synthesis – In healthy adults, about 1 gram of cholesterol is 
synthesized and 0.3 gram is consumed per day. The body maintains a relatively constant 
amount of cholesterol (150-200 mg/dL). This is done mainly through controlling the level of 
de novo synthesis. Dietary intake of cholesterol in part regulates the level of cholesterol 
synthesis. Both of these cholesterols are then used in the formation of membranes and in the 
synthesis of the steroid hormones and bile acids (Croft et al, 1988). Bile acid synthesis uses 
most of this cholesterol.  
 
Three separate mechanisms regulate the body’s constant supply of cholesterol from cells 
(Kaplan & Pesse, 1989):  
1. “Regulation of HMG-CoA Reductase (HMGR)”  
2. “Regulation of extra intracellular free cholesterol via Acyl-CoA cholesterol 
Acyltransferase (ACAT)”  
3. “Regulation of cholesterol levels in plasma via HDL-mediated reverse transport and LDL 
receptor-mediated uptake”    
 
The cholesterol pool of the liver is used in two important ways. The liver utilizes part of it to 
produce bile salts, to be stored in the gallbladder as a part of the bile and ends up in the gut. 
There, the bile salts are involved in the emulsification of fats and their ingestion and 
absorption.  The rest of the cholesterol is used for other requirements of the body. To do 
this, the liver combines cholesterol from its pool with triglycerides and covers it with a 
particular protein so that it could be dissolved in the blood. These are somewhat large 
molecules, known as VLDL (very low density lipoproteins). The liver then drains them into 
the blood. 
  
Lipoprotein lipase (LPL) exists in abundance all over the body, especially in the walls of the 
arteries.  This enzyme is involved in removing triglycerides from VLDL cholesterol.  In the 
process, the VLDL shrinks in size and a relatively larger portion of it is made up of what is 
called intermediate density lipoproteins, or IDL.  
  
Low Density Lipoprotein (LDL) – As the process continues, and more triglycerides are taken 
away, what is left is a dense molecule referred to as low density lipoprotein (LDL). This 
lipoprotein still maintains a large amount of cholesterol. The protein layer allows the tissues 
to use this cholesterol.  It is the receptors on these tissues that make this interaction possible. 
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In the tissues such as that of the liver, and the inner layer of the arterial wall cholesterol is 
taken away from low density lipoproteins. 
 
 Free radicals in the body are very reactive and oxidative compounds that can oxidize low 
density lipoprotein cholesterol and help atherosclerotic plaque to form in the arteries. 
Antioxidants in the body can inhibit this process (Jialal, 1998). Vitamins such as A, C, and 
E, and other nutritious food we eat are important sources of antioxidants. Antioxidants are 
able to fight production and oxidation of free radicals. Some of these vitamins such as A, E, 
and C help to decrease LDL cholesterol oxidation and lower generation of these radicals.  
 
Oxidized low density lipoproteins are not generally wanted. This is because macrophage 
cells can readily identify them with their receptors. When there is an inflammation due to 
injury, they gang up on the site. The endothelial layer in large and medium cells of the 
arteries is one of such sites. There, with the help of their receptors, macrophages hunt and 
absorb the oxidized LDL. This turns them into foam-like cells that can not function any 
longer and perish in the tissues. This is the early indication of atherosclerotic plaque in the 
arteries.  
 
High Density Lipoprotein (HDL) – The liver also produces another type of lipoprotein, 
named high density lipoprotein. This is different from VLDL, which is also produced in the 
liver. It has little triglyceride and cholesterol, and has a particular protein covering.  High 
density lipoprotein collects the surplus cholesterol that cholesterol metabolizing cells can 
not utilize. Lecithin-cholesterol acyl transferase is an enzyme that is responsible for 
transporting surplus cholesterol back to HDL molecules. Unused cholesterol from arteries, 
liver, and other tissues are absorbed by HDL cholesterol. There is evidence that even some 
oxidized LDL can be removed by the LCAT and HDL cholesterol (Höckerstedt et al, 2004).  
As HDL circulates in the body and collects the cholesterol from tissues, it becomes mature 
and goes back to the liver. There, it is identified by its lipoprotein covering and is lodged in 
the liver’s cholesterol pool.   
 
Apo A-I –  Apo-A-1 is the main apolipoprotein in HDL cholesterol and performs a key 
function:  it collects surplus cholesterol from the outer cells and transports it back to the 
liver. It also has antioxidant and anti-inflammatory properties (Nissen et al, 2003). Apo-
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B/Apo-A ratio is an indicator of cardio vascular risk.  The higher the ratio, the higher the 
probability of cholesterol deposits in the walls of the arteries (Walldius and Jungner, 2004). 
 
Apo B –  Apo B is found in all of the atherogenic particles; VLDL, IDL, as well as large and 
small dense LDL cholesterol. They all have one Apo-B molecule inside them. The number 
of Apo B, therefore, is an indicator of the number of the above particles. Apo B helps to 
capture these particles from the walls of the arteries.  On the other hand, the Apo B formed 
in the liver helps with stabilization and transfer of cholesterol and triglycerides in plasma 
IDL, VLDL, and sd-LDL, and with the collecting of cholesterol in the liver and the outer 
tissues.  Of all the Apo B particles in the blood, over ninety percent are in low density lipid 
cholesterol. Low to normal LDL cholesterol may indicate an increase in highly atherogenic 
sd-LDL particles that are readily oxidized, leading to increased formation of plaques on the 
arteries walls. Apo-B/Apo-A ratio is an indicator of cardio vascular risk. The higher the 
ratio, the higher the probability of cholesterol deposits in the walls of the arteries (Walldius 
and Jungner, 2004). 
 
 
3-5-3-2   Probiotics’ mechanism of action on lipids 
It has been proposed that when probiotics settle in the gut, they ferment indigestible 
carbohydrate from food. Their action raises the short-chain fatty acids (SCFA) in the gut 
(St-Onge et al, 2000).  SCFA are produced from peptide, polysaccharide, protein, and 
oligosaccharide, mainly by anaerobic bacteria, and are the final product of bacteria’s activity 
in the GI tract. In terms of quantity, carbohydrates are the main source of short-chain fatty 
acids (ST-Onge et al, 2000). These large molecules get depolymerised by a variety of 
hydrolytic enzymes that are produced by bacteria and allow the organisms to ferment their 
sugar content. SCFA can lower the lipids in blood through blocking synthesis of hepatic 
cholesterol and/or through redirecting plasma cholesterol toward the liver (De Preter et al, 
2006).  
A hundred to 450 mmol of the SFCA is produced in the large intestine every day “with 
relative proportions of acetate, propionate, and butyrate being about 60:20:15 depending on 
the substrate” (ST-Onge et al, 2000). While Acetate seems to increase total cholesterol, 
propionate increases glucose in the blood and reduces hypercholesterolemia response caused 
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by acetate. Propionate does that by decreasing its use by the liver, for cholesterol and fatty 
acids synthesis.  
 
Micelles, which play a role in the absorption of cholesterol in the intestine, are produced by 
bile salts, cholesterol, and phospholipids.  By producing bile acids through deconjugating 
the bile salts in the small intestine, probiotics prevent micelle production. When cholesterol 
enters the enterohepatic circulation, it is dealth in the same way. 
 
Probiotics by using hydroxy steroid dehydrogenase, and conjugated bile acid hydrolase 
enzymes, breakdown the bile acid and hydrolyze bile salts. By doing so bile acids’ 
enterohepatic circulation will be disrupted (De Boever et al, 2000; Doncheva et al, 2002; 
Ahn et al, 2003). Hydroxy methyl glutarate CoA (HMG CoA) is another compound that 
helps probiotics block HMG CoA reductase activity, which is a rate limiting enzyme and is 
involved in endogenous production of cholesterol.   
Probiotic bacteria reduce absorption of cholesterol in the intestine by binding and hence 
incorporating it to the cell membrane. Cholesterol can also be assimilated during growth 
(Noh et al, 1997). All of the above mentioned activities together help with the cholesterol 
lowering actions of probiotics. 
 
 
 
 
3-6  Probiotics and antioxidative property 
Before reviewing the studies on antioxidant property of some probiotic strains, a summary 
on oxidative stress will be presented. 
 
3-6-1  Oxidative stress   
Within every cell there takes place chemical reactions that involve oxidation and reduction 
of molecules. These result in creation of electronically charged molecules, referred to as 
free radicals. These charged particles need to be neutralized. The unpaired electron inside 
the free radicals induces them to look for and capture electrons from other molecules 
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(McCorde, 2000).  Free radicals are normal byproducts of natural processes in the body, 
such as inflammation and oxygen metabolism. When cells in our body use oxygen to 
produce energy, for instance, free radicals are produced as a result of creation of ATP by 
the mitochondria.  Physical exercise can contribute to the upward movement in the number 
of free radicals.  Factors such as radiation and toxins also can contribute to the production 
of free radicals. Lifestyle and habits like excessive drinking and smoking, also lead to the 
creation of free radicals in the body. Free radicals can come together and produce other 
compounds that are even more harmful and destructive such as peroxynitrite (McCorde, 
2000). 
There are, thus, two aspects to free radicals, one is physiological and the other is 
pathological.  On the one hand they play a role as regulatory and signaling particles and 
have an important role in gene transcription.  On the other hand, they act as very 
destructive and oxidants (Fridovich, 1999).  For example, nitric oxide (NO) – a nitrogen 
free radical – is found everywhere in our body and that participates in every single organ 
and cell activity.  Endothelial cells produce physiologic levels of nitric oxide. That is vital 
for the regulation of “leukocyte adhesion, proliferation and relaxation of vascular smooth 
muscle cells, angiogenesis, thrombosis, platelet aggregation, vascular tone, and 
hemodynamic” (Ignarro et al, 1999).  
Furthermore, nitric oxide that neurons produce acts as neurotransmitter, and that which 
stimulated macrophages produce serves as an essential mediator of the immune response 
(Valko et al, 2007, Fridovich, 1999). Nevertheless, Free radicals, however, that act as 
oxidants and disrupt the function of enzyme that have an iron-sulfur center, interact with 
important organic molecules such as proteins, lipids, and DNA. These biomolecules are 
damaged by oxidation and as a result they cannot function properly, which could cause of 
various diseases (McCord, 2000).  
 
Reactive Oxygen Species (ROS) – Reactive oxygen species refers to all molecules that are 
extremely reactive and have oxygen in them. Free radicals belong to these species. The 
superoxide anion radical (O2.-), the hydroxyl radical (OH.), hydrogen peroxide (H2O2), nitric 
oxide radical (NO.), singlet oxygen (-1O2), hypochlorite radical (HOCl), and lipid peroxides 
are different types of reactive oxygen species. They can enter into chemical reactions with 
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enzymes and proteins, nucleic acids, membrane lipids, and other tiny molecules, which 
cause cellular damage (Figure 6-3-1).  
 
A number of pathways generate ROS. Most of the oxidants produced by cells occur as a 
result of: (Fridovich, 1999; Percival, 1996)  
• Phagocytes Oxidative disintegration; mechanism which bacteria, viruses and foreign 
proteins (antigens) are destroyed or denatured,  
 • Normal aerobic metabolism; which oxygen is used by the mitochondrial electron 
transport system,  
• Metabolism of Xenobiotic; which through it lethal compounds are neutralized. 
 
 
 
Figure 3-6-1   ROS produced in vascular tissue 
O2−, superoxide; NO, nitric oxide; ONOO−, peroxynitrite; H2O2, hydrogen peroxide; OH−, hydroxyl radical; 
SOD, superoxide dismutase; GSH, reduced glutathione; GSSG, oxidised glutathione; VSM, vascular smooth 
muscle. (Source: Hamilton et al, 2004) 
 
 
Oxidative stress – Oxidative stress is seen when the creation of ROS in a system surpasses 
its ability to neutralize and eradicate them. This may be the result of an absence of 
antioxidation ability due to its disruption in production or distribution. It may also be a 
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result of excess ROS caused by environmental factors or high risk (McCord, 2000). The 
following are among the factors that may contribute to an increase in the body’s oxidant 
load: “vigorous exercise, which fastens cellular metabolism; chronic inflammation, 
infection, and other illnesses; “leaky gut” pesticides, pollution, and insecticides” (Percival, 
1998). If not controlled appropriately, the excess ROS can damage a cell’s lipids, DNA or 
protein, preventing normal function. 
 
It seems that damage done to the cells by free radicals play an important role in aging and in 
other related degenerative diseases, like CVD, deterioration in the immune system, brain 
dysfunction, cancer, and cataracts. In general these radicals are believed to be involved in 
initiating numerous diseases (Willcox et al, 2004; Percival, 1998) 
  
Lipid peroxidation - One case of oxidative stress is in lipid peroxidation. The formation of 
lipid peroxidation products causes spread of free radical reactions Lipid peroxidation begins 
with hydrogen atom abstraction (Catala 2006). Hydroxyl radical, in its first reaction with 
PUFA produces a lipid radical (L●). This in turn reacts with molecular oxygen to produce a 
lipid peroxyl radical (LOO●) and create a second lipid radical; a lipid hydroperoxide (LOOH) 
(Catala 2006). Lipid peroxidation can cause changes in permeability of the membrane, 
transportation of different ions, and also may interrupt its metabolic process. This process of 
peroxydation produces a whole range of compounds. This process is one of the main results 
of the damage done to tissues through free radicals.   
 
Antioxidants – Formation of free radicals is naturally checked by a variety of useful 
compounds called antioxidants. Antioxidants in our body are the first to fight free radicals. 
The initial encounter leads to neutralization of free radical. Yet, another free radical is formed 
in this process. This begins a chain reaction. Before other free radicals are neutralized, 
thousands of reactions take place instantly. Antioxidants can stabilize, or deactivate free 
radicals before they attack cells and are vital in maintenance of systemic and cellular health. 
However, when there are not enough antioxidants to battle free radicals, the damage inflicted 
by oxidants accumulates and put the body’s well being in danger.  
 
A highly developed and complex system of antioxidant protection operates in the human 
body. The system has different endogenous and exogenous parts, which act interactively with 
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each other to combat free radicals (Valko et al, 2007). The various part of the system includes 
( Percival, 1998l): 
- Enzymes with antioxidant properties, such as glutathione reductase, glutathione 
peroxidase, superoxide dismutase, which are able to catalyze free radical reactions. 
-  Proteins with capability to bind to metals and act as antioxidant, such as albumin, 
lactoferrin, ferritin, and ceruloplasmin that sequester free copper ions and iron that are able 
to catalyze oxidative reactions. 
- Antioxidants with nutrient origin, such as ascorbic acid, carotenoids, tocopherols and 
tocotrienols, and other compounds like lipoic acid and glutathione. 
-  Other antioxidant, such as phytonutrients, which can be found in plants. 
  
Dietary antioxidants - Among dietary antioxidants, beta carotene, and vitamins C and E 
have been subject of extensive studies. Vitamin C is believed to be one of the major 
antioxidant which is dissolvable in water and exits in extracellular fluid.  It can deactivate 
reactive oxygen species in an early stage (in the “watery” phase), before peroxidation 
process (Percival, 1998). Vitamin E, on the other hand, is an important antioxidant that 
dissolves in fats. This vitamin is the most effective antioxidant in the cell membrane that can 
keep fatty acids from being peroxydized and breaks the chain. Carotenoids, especially, beta 
carotene shield lipid-rich tissues from peroxidation. There are other antioxidants in our diets 
such as phytochemicals which have been increasingly mentioned for their antioxidant 
activity. Flavonoids have shown the ability to act against allergens, some infections and 
inflammation (Balz, 2004). 
 
Endogenous antioxidants - Dietary antioxidants are not the body’s only line of defense. A 
number of other mechanisms are also involved in protecting tissues from free radicals, 
which are endogenous. The antioxidant enzymes such as catalase, glutathione peroxidase, 
and superoxide dismutase are involved in metabolizing oxidative toxic intermediates. In 
order to utilize their maximum catalytic potential, they need cofactors like zinc, iron, 
copper, selenium, and manganese. 
 
Assessments of free radical activity - There are a number of complex methods for assessing 
free radical activity.  There are no “gold standard” assays of free radical activity, however.  
Three major approaches have been used (Jackson, 1999; Fang, 2002): 
- “Measurement of endogenous antioxidant”,  
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- “Measurement of oxidized macromolecules products”,  
- “Detection of free radicals directly”, 
In order to assess endogenous antioxidant capacity, most studies have measured the plasma 
or cell levels of antioxidants such as carotenoids, vitamin E, folate, vitamin C, glutathione, 
and zinc. They have also examined the activities of enzymes with antioxidant properties, 
such as superoxide dismutase, glutathione reductase, catalase, and glutathione peroxidase. 
Because radicals and other reactive species quickly oxidize glutathione to glutathione 
disulfide (GSSG) and GSSG is exported from cells, intracellular ratio of glutathione (GSH) 
to GSSG may be taken as a reliable indicator of oxidative stress (Jackson, 1999).  
 
Assessing peroxidation of lipids entails analyzing lipid peroxides, diene conjugates, 
isoprostanes, and breakdown products of lipids such as, pentane, MDA, and 4-
hydroxynonenal.  Of these, malondialdehyde is used most and is believed to be a true index 
of peroxidation of lipids. In the case of protein oxidation, the majority of researchers have 
made assessments based on “protein carbonyls”, “nitration of protein-bound tyrosine 
residues”, and the “loss of free thiol groups in proteins” (Fang, 2002). They have 
extensively used protein nitrotyrosine as a handy for measuring the production of reactive 
oxidants with nitrogen such as nitric oxide.  
 
Certain DNA base oxidation compounds like 5-OH cytosine, 8-OH adenine, 8-OH guanine, 
and 8-hydroxydeoxyguanosine, have frequently been used as an indicator in order to 
evaluate oxidation of DNA. In addition, 8-hydroxydeoxyguanosine (urinary excretion) may 
give a valuable tool to determine DNA base oxidation in animals and humans (Jackson, 
1999).  Direct detection of free radicals has been done by “spin trapping” techniques and 
“electron spin resonance”.  
 
 
 
3-6-2  In vitro studies; mechanism 
Noh and Gilliland (Noh and Gilliland, 1993) have demonstrated lactobacilli’s capacity to 
function as antioxidants. They have further shown that this can be measured based on how 
much they can shield ß-phycoerythrin from oxidation by free radicals. The cell-free extracts 
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of the cultures showed the highest level of antioxidant capacity. This could indicate the 
import role of this bacteris in the GI tract in providing and releasing antioxidants.   
 
 
Lin and Yen examined 19 strains of lactic acid bacteria for antioxidative activity (Lin and 
Yen, 1999). These bacteria included; “Streptococcus thermophilus 821, MC, 573, 3641, 
Lactobacillus acidophilus B, E, N1, 4356, LA-1, and Bifidobacterium longum B6 and 15 
708, and Farr; Lactobacillus bulgaricus 12 278, 448, 449, Lb, 1006, and 11 842; and 19 
987”. All strains showed 7-10% inhibition rate for ascorbate autoxidation.  Different 
mechanisms were under study for the antioxidative activities were: scavenging the ROS, 
restriction of enzyme’s activities, chelating ability of metal ions, and intracellular cell-free 
extract activities of lactic acid bacteria. Among the 19 strains that were tested the utmost 
capability for chelating Cu2+ belonged to “B. longum 15 708” and the highest capability for 
chelating ion Fe2+  was observed in S. thermophilus 821.  All of the 19 strains were capable 
to scavenge ROS.  The highest scavenging activity for hydrogen peroxide was shown in  B. 
longum B6, while for hydroxyl radical the highest activity was observed in L. acidophilus E. 
Although all strains showed reducing activity, B. longum B6 had the highest activity.  None 
of the strains showed superoxide dismutase activity and the metal ions Cu2+ Zn2+  or Mn2+, 
Fe2+  did not stimulate its activity either. 
 
 
In another study by Lin and Chang (Lin and Chang, 2000) two strains of intestinal LAB; L. 
acidophilus (ATCC 4356) and B. longum (ATCC 15708) were studied.  The antioxidative 
activity of intracellular cell-free extracts and intact cells of these bacteria was observed in 
both strains. They also inhibited linoleic acid peroxidation by 28–48%. The two strains also 
demonstrated that they were capable to scavenge free radical, a,a-diphenyl-b-picrylhydrazyl 
(DPPH).  4-nitroquinoline-N-oxide (4NQO) activity was inhibited by the intact cells of 
these two bacteria; 50% by L. acidophilus and 90% by B. longum. Intracellular cell-free 
extracts of none of the bacteria showed cytoxicity inhabitation. Both strains showed 
between 11% and 29% protection for plasma lipid oxidation.  Over all, B. longum 
demonstrated better antioxidative ability than L. acidophilus. 
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Extracellular polysaccharides (EPSs) are among major biomolecules that have antioxidant 
properties.  Probiotic bacteria synthesize EPS. Different techniques and methods have been 
used to investigate the free radical scavenging ability and antioxidant activity of isolated 
EPS. They were compared to known antioxidants vitamin E and C, which were applied as 
reference standards. The results indicated a high free radical scavenging and antioxidant 
activities for the EPS, which was produced by B. coagulants RK-02 (Kodali and Sen, 2008). 
  
 
3-6-3  In vivo studies 
Animal studies: 
Through in vitro screening, lactic acid bacteria that had antioxidative properties were chosen 
(Kaizu et al, 1993). Antioxidative activity of these bacteria, including Bifidobacterium, was 
assessed through an animal study using vitamin E deficient rats.  Out of 570 strains, 19 
showed antioxidative activity in the 1st phase of screening. In the 2nd phase, 7 of 
lactobacilli strains showed more than 70% inhibition rate of oxidation activity. 
Lactobacillus sp. SBT 2028 demonstrated the highest activity.  Intracellular cell-free extracts 
of  “Lactobacillus casei ssp. rhamnosus SBT 2257” and  “Lactobacillus sp. SBT 2028” were 
assessed for changes in condition of rats with vitamin E deficiency. In those rates which 
were fed the extract of Lactobacillus sp. SBT 2028, blockage in hemolysis of red blood cells 
was observed. This indicated that the vitamin E deficiency status was improved by the 
extract. An extract from L. casei ssp. rhamnosus SBT 2257 showed somewhat weaker 
antioxidant activity than the Lactobacillus (Kaizu et al, 1993). 
To conduct an animal study on albino rats, Lactobacillus casei ssp. casei was chosen for its 
high antioxidative activity through an in vitro study (Kapila et al, 2006). Examining the 
plasma in groups of rat that were fed fermented milk showed that their cholesterol was less 
by 2-11%, compared to groups that were fed skim milk. The groups that were fed 
lyophilized culture showed a drop in cholesterol level of 15-25%, compared with skim milk 
fed rats. Among rats that were given fermented milk or culture, TBARS concentrations were 
lower in the LDL cholesterol fraction of plasma compared to the control group fed on skim 
milk. The results point at the hypocholesterolemic and antioxidative potential of 
Lactobacillus casei ssp. casei when used as dietary adjunct. 
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The effect of dahi (whole yoghurt with live culture) with probiotic “Lactobacillus casei 
NCDC19” and “Lactobacillus acidophilus NCDC14” on worsening of “streptozotocin 
(STZ)-associated diabetes” in rats was examined (Yadav et al, 2008). The experiment 
showed that, by blocking nitric oxide and lipid peroxide formation and through maintaining 
antioxidant pool such as glutathione content and activities of catalase, superoxide dismutase, 
and glutathione peroxidase, probiotic dahi significantly suppressed STZ-induced oxidative 
damage, in pancreatic tissues.  
Fifty-three “male Sprague-Dawley rats” were selected for a study on how probiotics affect 
inflammation, oxidative stress, and acinar cell (exocrine cells of the pancreas) injury in the 
early stage of acute pancreatitis (AP). The rats were assigned randomly to five groups: 
control, sham procedure, acute pancreatitis with no treatment, with probiotic treatment, or 
placebo (Lutgendorff et al, 2008). Oxidative stress causes injury to acinar cell and 
progresses the severity of AP, while prophylactic probiotics improve the condition.  The 
study showed that AP injury and oxidative damage were improved by administrating 
probiotics as compared to placebo. Compared to placebo, probiotics also decreased AP-
induced NF- B and lipid peroxidation. AP-induced glutathione depletion stopped compared 
to placebo, and probiotic pretreatment, it even increased glutathione compared to sham rats.  
Biosynthesis of glutathione increased because of administrating probiotics which may have 
lowered inflammation and injury to acinar cell. 
 
Human studies: 
Twenty-one volunteers were selected for a three-week trial in order to assess the effect of 
the probiotic “Lactobacillus fermentum ME-3” (Kullisaar et al, 2003). The volunteers were 
assigned into goats’ milk group or fermented goats’ milk group (150 g/d). Administration of 
fermented goat milk increased the protection against atherogenicity in the participants. It 
increased resisting period against oxidation in lipoprotein fraction, and decreased oxidized 
LDL level, peroxidized lipoproteins, 8-isoprostanes and glutathione redox ratio. It also 
improved total antioxidative activity. The quantity and ratio of lactic acid bacteria species 
changed in the gut microflora as a result of administration of fermented goats’ milk. 
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In order the examine the functional efficacy of “Lactobacillus fermentum ME-3”, a 
probiotic strain,  two trials for 3 weeks were performed on healthy volunteers (Songisepp et 
al, 2005). The effect of two different interventions on oxidative stress markers of blood and 
urine, intestinal lactoflora, and fecal recovery of the probiotic bacteria were assessed.  In the 
first open placebo controlled investigation, subjects administered either fermented goat milk 
by L. fermentum ME-3 or ordinary goat milk.  In the second study which was double blind 
randomized placebo controlled, subjects were given either placebo capsules or capsules with 
L. fermentum ME-3. Recovery of ME-3 in feces was recognized only in the fermented milk 
group, by molecular methods. On the other hand, there was observed a significant increase 
in total antioxidative status (TAS) and total antioxidative activity (TAA) in capsules and 
fermented milk. Yet, the decrease of glutathione re-ox ratio values was shown only in 
probiotic containing fermented milk. 
 
In order to evaluate the effect of probiotic yoghurt on oxidation parameters in plasma of 
human, a cross-over randomized clinical trial was carried out (Fabian and Elmadfa, 2007). 
Subjects were randomly allocated into two groups: conventional yoghurt and probiotic 
(Lactobacillus casei) yoghurt groups. Volunteers consumed 100 g/day of probiotic or 
conventional yoghurt for two weeks and 200 g/day for another two weeks. This was 
followed by a two-week wash-out period.  The results showed a significant reduction in 
total antioxidant capacity values and increase in malondialdehyde and conjugated dienes 
(CD) values in both tested groups. While superoxide dismutase activity remained unchanged 
in both yoghurt groups, catalase and gluthathione peroxidase activity significantly decreased 
in probiotic consuming group after four weeks. There were no statistically significant 
differences between the two yoghurt consuming groups, even though some parameters 
altered throughout the study. 
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Summary 
Most lactic acid bacteria have systems to deal with oxygen radicals. Certain types of 
lactobacilli and bifidobacteria have been noted to produce antioxidative activity. Different 
antioxidative mechanisms under study in lactic acid bacteria include; scavenging the ROS, 
inhibiting enzyme activity, restriction of enzyme’s activities, chelating ability of metal ions, 
and intracellular cell-free extract activities. Most strains have demonstrated very good 
reducing activity.  Ability for chelating metal ions such as Cu2+ or Fe2+ has been shown by 
some LAB strains.  The physiological chelators in the “intracellular cell-free extract” of 
LAB strains could be the reason for chelating ability of these bacteria. Other mechanism to 
deal with ROS is SOD and high internal concentrations of Mn2+.  In other species blocking 
the peroxyl radicals is done through production of catalse. The fact that LAB can produce 
this minimum oxidation-reduction ability – ability required if they are to grow fully – is 
perhaps related to a number of the above mentioned systems.  
There are very few studies on antioxidative effects of probiotics in humans. Studies 
reviewed in this section show promising result on the effects of some strains of bacteria on 
humans, but there certainly is a need for more in vivo studies on different strains of lactic 
acid bacteria. 
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4    METHODOLOGY  
4-1  Study design 
This study was designed as a permuted blocked randomized trial. There were three parallel 
groups and the study was conducted for 6 weeks. Ninety healthy women volunteers who 
meet the criteria to enter the study were randomly assigned into three groups, 30 in each 
group. The first group consumed 300 grams of probiotic yoghurt per day, the second group 
consumed 300 grams of conventional yoghurt, and the third group did not consume any 
yoghurt for 6 weeks. The study was triple blind for yoghurt consuming groups. 
 
4-2  Sample size  
Based on the equation below, the sample size needed for this study was 30 in each group, a 
total of 90 samples for all.   
Assuming α = 0.05, β = 0.2, 1- β = 0.80, and considering the change in mean and standard 
deviation of cholesterol based on a similar study (S = 0.16 and δ = 0.1), the sample size was 
determined. (Ataie-Jaafari et al, 2005)  The sample size was calculated based on the 
equation below: 
 
                    (Z1-α/2 + Z1-β)²  S²   
n   =     ---------------------------- 
                             δ² 
 
Based on the equation, the sample size needed for this study was calculated as 20 for each 
group. Considering the effect of other variables in the study, and given the differences in the 
results of other studies, we multiplied the sample size by 1.5.  As a result, the sample size 
for each group was 30 and the total sample size was 90. This would increase the power of 
the study. Two subjects had to be excluded from the study after the first week because of 
taking antibiotics, one from the probiotic group and one from the control group. The 
demographic and blood lipid parameters of dropouts were not different than those subjects 
who completed the study. 
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4-3  Sampling Criteria 
Volunteers were recruited from the students and personnel of Tehran University of Medical 
Sciences through advertising at the university. The inclusion and exclusion criteria to enter 
the study were as follow: 
 
Inclusion Criteria:  
- Triglyceride less than 200 mg/dl 
- Cholesterol less than 240 mg/dl 
- Body Mass Index (BMI) up to 30 
- Females between 19-49 years old (pre-menopausal) 
 
Exclusion Criteria: 
- Having hypercholesterolemia, diabetes mellitus, thyroid disorders, or 
immunodeficiency diseases  
- Having the history of a myocardial infarction, angioplasty or stroke  
- Using anticoagulants, immunosuppressant, corticosteroids, thyroid replacement and 
hypercholesterolemia medication 
- Having lactose intolerant  
- Consumption of probiotic yoghurt or any other probiotic containing products in the 
last  month 
- Pregnancy or having plans to become pregnant during the time course of the study or 
lactating  
- Smoking 
- Having kidney or liver disease, inflammatory intestinal disease  
- Elite athletes 
- Use of any antimicrobial agent within the last month before the study, or use of any 
regular concomitant medication including antioxidant supplement, vitamins, and 
anti-inflammatory non-steroidal drugs were excluded 
- Having special diet (vegetarian, vegan, etc) 
 
Volunteers were checked to see if their complete blood counts (CBC) were normal and if 
their cholesterol and triglyceride level and other criteria met the criteria to enter the study. A 
one-week pre-adjustment period was designated, during which all subjects had to refrain 
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from taking yoghurt or any other fermented food. Written informed consent was taken from 
each volunteer who took part in this study. Subjects were randomly assigned into three 
groups, each group consisting of 30 individuals. The first and second groups consumed 300 
grams, per day, of probiotic and conventional yoghurt, respectively. The third group, as the 
control group, did not consume any yoghurt for the duration of the study (45 days). 
Required information was given to conventional and probiotic yoghurt consuming groups 
on proper storage and use of the products. 
 
The volunteers were told not to alter their daily physical activity or diet, and not to use soya 
milk and not to add high fiber items into fermented milk, and not to consume any other 
yoghurt other than the one provided. They were also asked to refrain from consuming any 
other probiotic products. Weekly follow up on use of study products, amount of exercise 
and use of any medication was performed.  Necessary arrangements were made so that 
every week the subjects would receive a week’s supply of their probiotic or conventional 
yoghurts directly from the factory. The Ethics Committee at TUMS approved the study’s 
protocol. 
 
4-4  Probiotic yoghurt 
Both conventional and probiotic yoghurts were produced by the Research and Development 
(R&D) Division of Iran Dairy Industry Corporation, (IDIC-Pegah) Tehran.  IDIC is one of 
the major dairy manufacturers in Iran. Probiotic and conventional yoghurts supplied, both, 
contained L. bulgaricus and S. thermophilus. The probiotic yoghurt was also enriched with 
adding cultures of B. lactis Bb12 and L.acidophilus La5 (by Christian Hansen).  Direct vat 
set cultures were used.  Microbiological analysis of the probiotic yoghurt showed that it 
contained 3.9 × 107 (cfu) of both B. lactis Bb12 and L.acidophilus La5. The analysis on 
conventional yoghurt confirmed the presence of 106-107 cfu of S. thermophilus and L. 
bulgaricus.  The yoghurts’ acidity was 4.3. The fat content in both yoghurt types was 2.5%. 
 
Those in conventional or probiotic yoghurt group were provided to consume 300 gram per 
day. The yoghurts were presented in identical plastic cups containing 150 gram yoghurt. 
Each container had a different color top that indicated the intervention group. It was not 
known to the subjects, researcher, and analyzer which container contained probiotic or 
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conventional yoghurt. A third party had the enclosed intervention codes, which were 
revealed after the analyses were done.  
 
4-4-1  Some characteristics of LA5 and BB12 
LA-5 is facultative anaerobic, so it is able to function in the presence or absent of oxygen. It 
is able to grow in very acidic environments. BB-12 is only function anaerobically. Lactic 
acid is not the only acid it produces. Succinic and acetic acids are also products of BB-12. 
Both of them give a feeling of desirable fresh taste.  
The reason for selection of these probiotic strains (by Hansen) was because the following 
criteria were met: 
a)  Technological properties  
- Single strains can be produced as highly concentrated DVS culture for the direct 
inoculation of milk 
- Good technological characteristics in production of acidified and unacidified 
probiotic dairy products  
- Both strains show fermentation activity in milk (i.e. among other things acidification 
and lactose utilization). 
- The strains show a high survival ability in the unacidified and acidified product 
during cool storage 
 
b) Resistance during the gastrointestinal passage; (Wang et al, 2004; Ouwehand et al, 
2001) 
- LA-5 has shown a survival ability of “100% at a pH of 3.0 and 4.0 over 2 hours. At a 
pH of 2.0 the survival ability was reduced by 2 log values”, 
- BB-12 has shown a survival rate of “100% at a pH of 2.0. After 2 hours only a slight 
drop was detected”, 
- In vitro studies both strains have shown a high survival rate during the 
gastrointestinal passage, when administrated through cultured milk products (Klaver 
and Van Der Meer, 1993; Noh and Gilliland, 1993).   
 
c)  Activity and adhesion in the intestine 
By means of adhesion to the inner surfaces of the intestinal tract, probiotic bacteria can 
inhibit the colonization of other, partly pathogenic microorganisms. Furthermore, adhesion 
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extends the period for interactions between probiotic bacteria, intestinal flora and the 
intestinal tract’s immune system. Good adhesion ability to the cells of the colon epithelium 
or to the mucosal layer which lies thereon is thus an important selection criterion for 
probiotic bacteria. LA-5 and BB-12 show good adhesion ability to human mucous 
(Kirjavainen et al, 1998; Ouwehand et al, 2000). 
 
In addition lactic and acetic acid, hydrogen peroxide (H2o2) and bacteriocins belong to 
these substances. These are proteins which inhibit only a small number of mostly closely 
related bacterial strains without damaging the intestinal flora as a whole. Apart from small 
amounts of H2O2, LA-5 also produces acidocin CH5, a broad spectrum bacteriocins 
(Chumchalova et al, 1998) which also inhibits certain yeast. 
 
4-5  Data collection 
The subjects were asked to be present the Department of Nutrition and Biochemistry of 
School of Public Health at Tehran University of Medical Sciences, at three intervals; at the 
beginning of the study, at the end of the third week, and at the end of the sixth week.  
Information on anthropometric measurements, food consumption (through 3-day dietary 
record), and fasting blood samples were collected at three intervals. Compliance with the 
yoghurt intake guidelines at home was monitored once a week through phone interview.   
 
4-5-1  Anthropometric measurements   
At the beginning, at the end of the third week, and at the end of the sixth week (end of the 
intervention) anthropometric measurements of the subjects were taken. Body weight and 
height were measured with Seca scale and non-stretchable tape. At each interval, body 
weights were measured with 0.1 kg accuracy without shoes and with minimum clothing. 
Heights were measured, with 0.1 cm accuracy. BMI was determined by dividing body 
weight by height squared (kg/m2).  
 
4-5-2  Dietary records 
Prior to the intervention, those who enrolled in the study were taught by a dietician how to 
record the amounts of foods that were eaten. A written instruction was also given to them. 
At the beginning of the study, at the end of the third, and at the end of the sixth weeks, 
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three-day dietary records were taken from each volunteer who was directed to write down 
the types and amounts of foods eaten. The amount of food eaten by each subjects was 
estimated from household measures and from photos of serving sizes (Ghafarpour et al, 
1999).  Subjects were instructed to maintain their usual dietary habits and their exercise 
patterns throughout the experiment. Weekly follow ups were performed by phone. A 
nutritionist checked the participants’ dietary records in person upon their periodically visits 
to the Nutrition Department at TUMS for anthropometric measurements and blood 
sampling at the beginning of the study, at the end of third and sixth weeks of study.  The 
dietary records were analyzed for individual nutrients ( total energy, total fat, saturated fatty 
acid, polyunsaturated fatty acid, monounsaturated fatty acids, dietary fiber, vitamin A, C, 
and E)  using the computer based program, Food Processor II.  
 
 
4-5-3  Biochemical measurements 
Blood samples were drawn from the subjects in the morning after 14 hours of fasting at the 
three intervals; at the beginning of the study, at the end of the third week, and at the end of 
the sixth week. Blood was taken from the antecubital vain in the arm. To prepare plasma, 
the blood (6ml) was collected into tube with anticoagulant agent; the rest (4ml) was 
collected into tube with no anticoagulant agent for preparing the serum. For the plasma, 
blood samples were centrifuged for 10 minutes at 3000 U/min. Plasma separated and red 
blood cells were acid washed 3 times with physiologic serum (4°C) and stored at -80°C for 
analysis. 
For serum, collected blood samples were left for 40 minutes in 30°C to allow them to clot. 
Then using a glass pasteur, the clot was loosened from the sides of the tube. They were then 
centrifuged at 3000 U/min for 10 minutes to separate the serum from the clotted cells and 
the resulting serum was stored (in 5ml micro-tubes) at -80°C for analysis.   
The blood was analyzed for: 
 
 
 
 
 
 
Dependant variables Methods 
Total cholesterol Enzymatic  
HDL cholesterol Enzymatic  
LDL cholesterol Enzymatic  
Triglyceride Enzymatic  
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Apolipoprotein A Immunoturbidometry 
Apolipoprotein B Immunoturbidometry 
Total antioxidant capacity Spectrophotometer 
Malondialdehyde Spectrophotometer 
Oxidized LDL  Eliza 
 
Serum total cholesterol and triglyceride concentrations were measured with Parsazmun’s 
kits (DiaSys, Germany) using an enzymatic method CHOD-PAP (cholesterol oxidase 
phenol 4-aminoantipyrine peroxidase) and GPO-PAP (glycerol phosphate oxidase phenol 4-
aminoantipyrine peroxidase) (Artiss and Zak, 1997; Cole et al, 1997). Low-density and 
high-density lipoprotein cholesterols were also measured with the Parsazmun’s kits (DiaSys, 
Germany) by an enzymatic method (Rifai et al, 1999). Apolipoprotein A-1 and 
Apolipoprotein B were analyzed by Immunoturbidometry method (Bhatnagar and 
Durrington, 1997).  Parsazmun’s kits (DiaSys, Germany) were used for Apo A and Apo B 
measurements.   
Plasma MDA was measured as an indicator of lipid peroxidation based on the thiobarbituric 
acid (TBA) spectrophotometric method that was introduced by Satoh (Satoh, 1978). Total 
antioxidant capacity was measured according to Rice-Evans and Miller (Rice-Evans and 
Miller, 1994).  The assay is depended on the hindrance of the absorbance of radical cations 
of 2,2'-azinobis(3-ethylbenzothiazoline 6-sulfonate) (ABTS) by antioxidants as a result of 
incubation of ABTS with a peroxidase and H2O2.. The Mercodia Oxidized LDL Eliza kit 
(Sweden) was used for quantitative measurement of oxidized low density lipoprotein.  
 
4-6  Statistical analysis 
Analysis of variance (ANOVA) was used in the evaluation of the data. The ANOVA was 
used to indicate any difference among the three groups or among the three intervals within a 
group. The normality of the distribution of variables was tested using the Kolmogorov-
Smirnov test. When the distribution was not normal, the Naperian Logarithm transformation 
of values was performed to make data fit to the normal distribution and then the ANOVA 
was applied. 
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Nonparametric test of Kruskal-Wallis was used for those distributions which were not 
normal. In that case, the data are expressed in medians and inter-quartile ranges (IQR) of the 
original variable; otherwise the data are expressed in means and standard deviations. 
Multiple comparisons were done with the Bonferroni post-hoc test. Linear relationships 
between serum values were examined using Pearson’s correlation coefficient. Statistical 
Package for Social Sciences (SPSS/PC version 11.5) was used for the statistical tests. Food 
Processor (FPII, version 2) was used for calculating the dietary record (FPII, version 2).  
The differences were considered statistically significant at P < 0.05.  
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5   RESULTS 
 
 
To compare the mean of variables among the three groups and within each group throughout 
the study, analysis of variance (ANOVA) was applied. The normality of the variables 
distribution was tested using the Kolmogorov-Smirnov test. Whenever the distribution was 
not normal by conducting Kolmogorov-Smirnov test, the Naperian Logarithm 
transformation of values was performed to make data fit the normal distribution. For 
distributions that were not normal the nonparametric test of Kruskal-Wallis was used to 
compare groups and the data were expressed in medians and inter-quartile ranges (IQR) of 
the original variable. Otherwise, the data were expressed as means and standard deviations.  
Multiple comparisons were conducted by the Bonferroni post-hoc test. Linear relationships 
between serum values were examined using Pearson’s correlation coefficient. A P-value less 
than 0.05 was considered to be statistically significant. 
 
In this chapter results will be presented in the following sections: 
5-1   General characteristic of subjects 
5-2   Dietary intakes of subjects 
5-3   Blood lipid parameters 
5-4   Blood oxidant and antioxidant parameters 
 
 
 
5-1  General characteristics of subjects 
The means and standard deviations (SD) of age, body weight, height and BMI of the 
subjects at the baseline are presented in Table 5-1-1. Body mass index is obtains by dividing 
weight in kilograms by height in meters squared. The normal range for BMI is between 20 
and 25. A value above 25 and 35 are overweight and obese, respectively.  In this study, the 
mean value of BMI was within the normal range for all the three groups at baseline. At the 
beginning of the study, there were no statistically significant differences in age, weight, 
height and BMI among the three groups - the groups consuming conventional yoghurt, 
probiotic yoghurt, and the control group.  
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Table 5-1-1.   Means and standard deviations of characteristics of the subjects at baseline 
                    
                    Groups 
 
    Variables        
Conventional 
yoghurt (n=30) 
Probiotic 
yoghurt (n=29) 
Control 
(n=29) 
 
P- value 
Age (year) 32.0 ± 6.8 35.2 ± 6.4 34.7 ± 7.5 0.173 
Body Weight (kg) 58.47 ± 6.78 60.68 ± 7.01 59.33 ± 7.26 0.478 
Height (cm) 159.40 ± 5.19 158.86 ± 6.04 158.11± 6.37 0.698 
BMI (kg/m²) 23.02 ± 2.44 24.03 ± 2.42 23.76 ± 2.99 0.317 
 
 
Means and SDs of body weight and BMI of the subjects, at the three intervals of the study; 
baseline (T1), end of third week (T2), and end of the sixth week (T3) were compared within 
each group (Table 5-1-2).  Mean values for body weight and BMI of the participants were 
constant throughout the study for all the three groups. The ANOVA did show significant 
changes in body weight and BMI of the subjects at the three intervals of the study, within a 
group. 
 
Table 5-1-2.    Means and standard deviations of weight and BMI of the subjects within 
each group during the study 
 
 
                       Intervals 
 
Variables     |   Groups 
Baseline  
(T1) 
3rd  weeks 
(T2) 
6th  weeks 
(T3) 
 
P- value 
Body 
Weight 
(kg) 
Conventional 
yoghurt 58.47 ± 6.78 58.45 ± 7.01 58.91 ± 7.15 0.958 
Probiotic 
yoghurt 60.68 ± 7.01 60.76 ± 7.14 60.88 ± 7.39 0.994 
Control 59.33 ± 7.26 59.30 ± 7.20 59.33 ± 7.30 1.000 
BMI 
(kg/m²) 
Conventional 
yoghurt 23.02 ± 2.44 23.01 ± 2.58 23.19 ± 2.55 0.954 
Probiotic 
yoghurt 24.03 ± 2.42 24.13 ± 2.52 24.04 ± 2.58 0.985 
Control 23.76 ± 2.99 23.74 ± 2.88 23.77 ± 2.85 0.999 
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5-2  Dietary intakes of subjects  
In order to find the differences among the three groups or changes within a group, data from 
three-day dietary record for intakes of total energy, total fat,  saturated fatty acid (SFA), 
monounsaturated fatty acid (MUFA), polyunsaturated  fatty acids (PUFA), cholesterol, beta 
carotene, dietary fiber, vitamin C, and E were studied. 
 
The means and standard deviations of total fat, SFA, MUFA, PUFA, dietary fiber, vitamin 
C, and E are presented in table 5-2-1. The ANOVA did not show any difference among the 
three groups at baseline for intake of total fat, saturated fatty acid, MUFA, PUFA, dietary 
fiber, vitamin C, and E (Table 5-2-1).   
 
USDA Dietary Guidelines of 2005 recommends that “total fat intake should count between 
20 to 35 percent of energy for adults” and “no more than 10 percent of energy should be 
from saturated fats”.  (A dietary guideline for Iranian population is under development.) 
Peoples’ diets vary in different parts of the world. Among the Mediterranean, fat intake 
could provide forty percent of the calorie. But, as saturated fat in the diet raises blood 
cholesterol, such diet must be low in saturated fat and have a high MUFA and fiber content.  
Foods from animals and some plants are high in saturated fat. One of the main causes of 
high blood cholesterol is dietary saturated fat.  In the present study, the mean value of 
percent of fat from energy was between 34 to 35 percent in all groups, at the baseline (Table 
5-2-1).   
Polyunsaturated and monounsaturated fats appear to have a positive effect on plasma lipid 
profile. The National Heart, Lung, and Blood Institute recommend that up to 20% of total 
daily energy should be from MUFA and up to 10% from PUFA. Double bonds in 
polyunsaturated fatty acids can help create free radicals. These free radicals can then react 
with oxygen and produce lipid peroxide compounds with unstable oxygen bonds similar to 
those in hydrogen peroxide.  Polyunsaturated fatty acids may have a protective effect 
against atherosclerosis but moderation in consumption is recommended. 
Monounsaturated fats decrease LDL cholesterol level and other blood lipids while raising 
the high density lipoproteinn cholesterol level. Monounsautrated fatty acids have these 
favorable effects on blood lipids even in diets containing as much as 35% fat, as long as one 
third or more of the fat is from MUFA. In the present study, the mean values of SFA, 
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MUFA, and PUFA from total energy were between 10 to11 percent in the three groups 
(Table 5-2-1). 
Fibers accelerate the movement of food in the colon and slow down simple carbohydrates’ 
absorption. Thus, they can reduce constipation and help regulate blood sugar and insulin 
sensitivity. Soluble fibers bind to bile acids and reduce blood cholesterol. Soluble fiber can 
also lower the LDL cholesterol. Daily Reference Intake (DRI) of fiber for women is 25 
grams per day. The mean value for dietary fiber was less than 25 for all the three groups but 
there were not statistically significant differences among the three groups at the baseline 
(Table 5-2-1). 
Carnitine is a tiny molecule that is vital for fat to reach mitochondria to be converted into 
energy. Synthesis of carnitine, in turn, requires vitamin C. This vitamin is also involved in 
cholesterol’s metabolism to bile acids and can increase the risk of gallstone (Higdon, 2003). 
Vitamin C is also a powerful antioxidant. The recommended amount by RDA for non-
smoker adult women is 75 mg/day. In this study, in the probiotic yoghurt group the mean 
value for vitamin C was 72 mg but in the two other groups the amount was higher than 75 
mg. There but there were not statistically significant differences among the three groups at 
the baseline (Table 5-2-1). 
Vitamin E is a fat-soluble, antioxidant vitamin. It also plays a role in regulation of gene 
expression, immune function, cell signaling, and other processes related to metabolism 
(Higdon, 2003).  There are eight forms of vitamin E in nature.  They have different levels of 
biological activity. Only alpha tocopherol can be utilized by the human. Recommended 
dietary allowance for vitamin E (Alpha-Tocopherol) for adult women is 15 mg (22.41 IU). 
In the present study, the mean value for vitamin E was 14.48 mg for the probiotic yoghurt 
group, and 15 mg for the other two groups.  There were not statistically significant 
differences among the three groups in vitamin E intakes at the beginning of the study (Table 
5-2-1). 
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Table 5-2-1.   Means and standard deviations of nutrient intakes according to 3-day dietary 
record at baseline for each group 
 
                   Groups 
     
    Variables        
Conventional  
yoghurt  
Probiotic 
yoghurt  Control  
P- 
value 
Total  fat  
(g) 64.72 ± 14.63 64.57 ± 13.74 68.54±23.46 0.629 
(% of 
energy) 34.02±4.96 35.74±5.43 35.72±5.58 0.369 
SFA  
 
(g) 21.19 ± 7.43 20.00 ± 5.85 22.35 ± 9.78 0.525 
(% of 
energy) 10.96±2.37 10.94±2.67 11.52±2.94 0.613 
MUFA  
 
(g) 19.31 ± 4.72 19.87 ± 4.77 20.42 ± 6.56 0.736 
(% of 
energy) 10.12±1.57 11.03±2.35 10.70±1.69 0.183 
PUFA  
 
(g) 21.96 ± 8.47 20.60 ± 6.18  21.29 ± 9.11  0.809 
(% of 
energy) 11.51±3.72 11.45±3.15 11.12±3.56 0.898 
Dietary Fiber  (g) 16.52 ± 5.40 16.68 ± 6.66 16.85 ± 7.12 0.981 
Vitamin C  (mg) 83.63 ± 54.08 72.46 ± 50.66 81.96 ± 54.81  0.689 
Vitamin E  
(α-tocopherol) (mg) 15.24 ± 6.49 14.48 ± 6.74 15.92 ± 9.64 0.778 
 
 
 
  
For intakes of total energy, cholesterol and beta-carotene distributions were not normal. 
Therefore, Kruskal-Wallis test was carried out to compare the baseline values of these 
parameters among the three groups (Table 5-2-2). The recommended daily energy intake is 
1940 calories a day for women.  In the present study the median for total energy intake of all 
the three groups was below 1940, but there were no statistically significant difference 
among them. 
Vitamin A is vital for the functioning of the immune system. This group of compounds is 
also involved in cell division, bone growth, reproduction, and vision (Higdon, 2003). Beta-
carotene and other carotenoids can be converted by the body into retinol (preformed vitamin 
A). Beta carotene is one of the most important natural forms of antioxidants and has 
immune-system-enhancing activity. There is no RDA for beta carotene. There were no 
statistically significant differences among the three groups. 
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According to USDA Dietary Guidelines of 2005, recommended cholesterol intake is less 
than 300 mg. The median value for cholesterol intake in the three groups was less than 300 
mg. There were no statistically significant differences between medians and IQRs of these 
parameters among the three groups at baseline.  
 
 
Table 5-2-2.   Medians and IQRs of energy, cholesterol and beta-carotene according to 3-
day dietary record at baseline for the three groups 
                   Groups 
     
    Variables        
Conventional  
yoghurt  
Probiotic 
yoghurt  Control  P- value 
Median (IQR)
Total energy (kcal) 1646.50 (579.75) 1686.00 (567.50) 1657.00 (555.0) 0.762 
Cholesterol (mg) 162.50 (139.75) 146.00 (138.00) 173.00 (173.50) 0.791 
β -carotene (mg) 1.75 (3.80) 1.49 (2.77) 2.00 (2.71) 0.437 
 
 
 
 
The intakes of total fat, saturated, monounsaturated, polyunsaturated fatty acids, dietary 
fiber, vitamin C, and E within each group at the three intervals are presented in Table 5-2-3. 
The ANOVA did not show any significant difference during the study, in the three intervals, 
for intake of these parameters.  
 
 
 
Table 5-2-3.   Means and standard deviations of nutrient intakes according to 3-day dietary 
record throughout the study for each group 
 
 
                        Intervals 
                           
Variables |   Groups 
Baseline 
(T1) 
3rd  week 
 (T2) 
6th  week 
 (T3) 
P- 
value 
Total  fat 
(g) 
Conventional 
yoghurt 64.72 ± 14.63  71.19 ± 21.40 66.67±16.60 0.355 
Probiotic 
yoghurt 64.57 ± 13.74 62.47±13.96 64.17±24.27 0.895 
Control 68.54 ± 23.46 65.59±25.73 64.75±17.11 0.796 
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Total fat 
(% of 
energy)  
Conventional 
yoghurt 34.03±4.96 34.67±6.86 33.90±5.32 0.859 
Probiotic 
yoghurt 35.74±5.43 33.55±7.09 33.81±5.86 0.342 
Control 35.72±5.58 34.98±5.61 35.11±6.31 0.878 
SFA (g) 
Conventional 
yoghurt 21.19 ± 7.43 23.05 ± 8.29 22.56 ± 7.46 0.630 
Probiotic 
yoghurt 20.00 ± 5.85 22.49 ±6.16 21.81±7.80 0.341 
Control 22.35 ± 9.78 19.84±7.54 20.49±6.86 0.482 
SFA 
(% of 
energy) 
Conventional 
yoghurt 10.96±2.37 11.15±2.70 11.33±2.22 0.841 
Probiotic 
yoghurt 10.94±2.27 11.89±2.60 11.52±2.02 0.292 
Control 11.52±2.94 10.61±1.58 10.86±1.95 0.283 
MUFA 
 (g) 
 
Conventional 
yoghurt 19.31 ± 4.72 21.44± 6.86 21.10 ± 6.22 0.340 
Probiotic 
yoghurt 19.87 ± 4.77 18.98±4.54 19.36±7.44 0.840 
Control 20.42±6.56 19.61±8.02 19.87±5.71 0.900 
MUFA 
(% of 
energy) 
Conventional 
yoghurt 10.12±1.57 10.46±2.52 10.66±1.83 0.582 
Probiotic 
yoghurt 11.03±2.35 10.15±2.04 10.19±1.86 0.199 
Control 10.70±1.69 10.46±2.19 10.78±2.41 0.836 
PUFA 
 (g) 
Conventional 
yoghurt 21.96 ± 8.47 22.53 ± 8.45 20.59 ± 9.08 0.674 
Probiotic 
yoghurt 20.60 ± 6.18 17.47±6.62 18.86±10.60 0.337 
Control 21.29 ± 9.11 21.93±11.02 20.07±7.63 0.744 
PUFA 
(% of 
energy) 
Conventional 
yoghurt 11.51±3.72 10.96±3.21 10.41±3.64 0.487 
Probiotic 
yoghurt 11.45±3.15 9.49±3.91 9.87±3.58 0.091 
Control 11.12±3.56 11.64±3.80 11.11±4.18 0.831 
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Dietary 
fiber (g) 
Conventional 
yoghurt 16.52 ± 5.40 17.93 ± 6.46 18.29 ± 8.75 0.590 
Probiotic 
yoghurt 16.68 ± 6.66 16.55 ± 6.98 14.79 ± 5.40 0.458 
Control 16.85 ± 7.12 17.15 ± 7.20 17.96 ± 8.41 0.848 
Vitamin 
C (mg) 
 
Conventional 
yoghurt 83.63 ± 54.08 78.08±46.00 77.10±47.64 0.859 
Probiotic 
yoghurt 72.46 ± 50.66 73.32 ± 48.98 81.66 ± 44.57 0.725 
Control 81.96 ± 54.81 83.56 ± 55.84 68.49 ± 52.82 0.515 
Vitamin 
E (mg α-
tocopherol)) 
 
Conventional 
yoghurt 15.24 ± 6.49 16.40 ± 8.02 15.84 ± 9.75 0.861 
Probiotic 
yoghurt 14.48 ± 6.74 13.45 ± 7.00 13.44 ± 8.82 0.836 
Control 15.92 ± 9.64 16.46 ± 9.09 16.17 ± 6.56 0.971 
 
In the present study, the mean value for percentage of fat from energy was between 33 and 
35 in all groups, at the three intervals. The mean values for SFA, MUFA, and PUFA from 
total energy were between 9 to11 percent in the three groups (Table 5-2-3). 
In western countries diets the ratio between polyunsaturated and saturated fatty acids is less 
than one. It is believed that increasing it to near one would lower the risk of CVD. The P/S 
ratios in all the three groups, during the three intervals of the study are as follow:  
 
 
 Baseline   3rd  weeks   6th  weeks  
Conventional yoghurt 1.03  0.95  0.91 
Probiotic yoghurt 1.03  0.78  0.86 
Control 0.95  1.10  0.98 
 
The lowest ratio belongs to the probiotic group at the second interval of the study (0.78), 
which is, higher than the ratio in diets in Western countries.  
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Since the distributions were not normal for total energy, cholesterol and beta-carotene, 
Kruskal Wallis test was used for those parameters to examine any significant change at the 
three intervals within each group (Table 5-2-4). The results show no statistically significant 
change in those parameters throughout the study within a group.  So, there was no 
statistically significant difference at the three intervals of the study for any of the dietary 
parameters. 
 
 
Table 5-2-4   Medians and IQRs of energy, cholesterol and beta-carotene intake according 
to 3-day dietary record throughout the study for the three groups  
                        Intervals 
                           
Variables |   Groups 
Baseline 
(T1) 
3rd  week 
 (T2) 
6th  week 
 (T3) 
P- 
value
Total 
energy 
(kcal) 
 
Conventional 
yoghurt 1646.5 (579.7) 1788.5 (569.7) 1731.5 (785.7) 0.392 
Probiotic 
yoghurt 1686.0 (567.5) 1636.0 (383.5) 1723.0 (633.5) 0.926 
Control 1657.0 (555.0) 1645.0 (743.5) 1622.0 (743.5) 0.873 
Cholesterol 
(mg) 
 
Conventional 
yoghurt 162.5 (139.7) 206.5 (161.7) 195.0 (222.0) 0.608 
Probiotic 
yoghurt 146.0 (138.0) 199.0 (134.5) 158.0 (170.7) 0.380 
Control 173.0 (173.5) 169.0 (106.0) 142.0 (136.5) 0.518 
Beta 
carotene  
(mg) 
 
Conventional 
yoghurt 1.8 (3.8) 2.2 (3.2) 1.7(2.5) 0.612 
Probiotic 
yoghurt 1.5(2.8) 1.9 (1.8) 1.4 (2.7) 0.669 
Control 1.9(2.7) 2.7(2.2) 1.6 (2.2) 0.071 
 
 
 
 
 
So far, two comparisons on dietary data have been presented; a) comparing baseline values 
between conventional yoghurt, probiotic yoghurt and control groups, and b) comparing 
values at the three intervals within a group. Furthermore, to detect any possible changes 
during the course of the investigation (6 week period) among the three groups, the 
differences between baseline means and sixth week means for each group were calculated 
and then the differences were compared among the groups. Results of comparing differences 
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between baseline (T1) means and sixth week (T3) means for dietary intake parameters are 
presented in Table 5-2-5.  The ANOVA did not show any significant difference among the 
three groups for mean differences.  
Comparing baseline (T1) and sixth week (T3) means showed that there was a decrease in 
the amount (g) of total fat intake of the probiotic yoghurt group and the control group and an 
increase in that of the conventional yoghurt group (Table 5-2-5). Comparing the 
percentages, however, showed decreases in three groups. There were increases in the 
amount and percentages of SFA in both yoghurt groups and decreases in the control group. 
The amount of MUFA decreased in the probiotic yoghurt group and the control group. 
There were increases in the percentage MUFA intakes in both conventional yoghurt and the 
control groups, while a decrease was observed in the probiotic yoghurt group. For PUFA, 
there were decreases in the three groups. Dietary fiber increased in the conventional and the 
control groups, but decreased in the probiotic yoghourt group. Vitamin C decreased in the 
conventional yoghurt group and the control group while it increased in the probiotic group. 
For vitamin E, there were increases in the mean values in the conventional yoghurt and the 
control groups and a decrease in the probiotic yoghurt group. None of the above mentioned 
changes were statistically significant among the three groups (Table 5-2-5). 
  
Table 5-2-5   Differences between baseline (T1) mean and 6th week (T3) mean of nutrient 
intakes for the three groups  
                     
                     Groups     
Variables  
Conventional 
yoghurt 
(T1-T3) 
Mean ± SD  
Probiotic 
yoghurt 
(T1-T3) 
Mean ± SD 
 
Control 
 (T1-T3) 
Mean ± SD 
P- value 
Total  fat (g) 1.95 ± 22.96 -0.40 ± 26.15 -3.79 ± 27.11 0.686 
Fat (% of energy) -0.12 ± 6.22 -1.93 ±7.30 -0.60±7.69 0.603 
SFA(g) 1.37 ± 7.45 1.81 ± 7.38 -1.86 ± 10.08 0.192 
SFA (% of energy) 0.37±2.45 0.58±1.57 -0.65±3.54 0.167 
MUFA (g ) 1.79 ± 6.70 -0.51 ± 8.30 -0.54 ± 7.19 0.386 
MUFA (% of energy) 0.54±2.09 -0.84±2.50 0.08±2.56 0.085 
PUFA (g) -1.37 ± 10.67 -1.74± 13.39 -1.22 ± 12.22 0.986 
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PUFA (% of energy) -1.10±3.69 -1.58±5.31 -0.01±4.94 0.428 
Dietary fiber (g) 1.76 ± 8.70 -1.88 ± 6.31 1.11 ± 9.11 0.194 
Vitamin C (mg) -6.53 ± 54.11 9.20 ± 62.59 -13.47 ± 52.82 0.300 
Vitamin E (mg) 0.60 ± 9.51 -1.03 ± 10.51 0.25 ± 10.31 0.809 
 
 
 
Kruskal-Wallis test showed no statistically significant difference among the three groups for 
median differences (T1 minus T3) for energy, cholesterol and beta-carotene (Table 5-2-6).   
There were increases in median intakes of total energy and cholesterol in both yoghurt 
groups and decreases in the control group.  Median intake of beta carotene decreased in all 
three groups. 
 
 
Table 5-2-6   Differences between baseline (T1) and 6th week (T3) median intakes of 
energy, cholesterol and beta-carotene according to 3-day dietary for the three groups  
 
                     
                     Groups     
Variables  
Conventional 
yoghurt 
(T1-T3) 
Probiotic 
yoghurt 
(T1-T3) 
 
Control 
 (T1-T3) P- value 
Median (IQR) 
Total energy (kcal) 55.00 (784.25) 44.00 (435.00) -62.00 (584.00) 0.721 
Cholesterol (mg) 29.25 (193.85) 5.70 (149.60) -26.00 (183.55) 0.228 
Beta carotene (mg) -0.21(2.69) -0.29(2.87) -0.01(2.52) 0.759 
 
 
In summary, there were no statistically significant differences among the three groups and 
the three intervals of the study for intakes of any nutrients and energy. The mean differences 
between baseline and six week also did not show any statistically significant differences 
among the three groups for nutrient and energy intakes. 
5-3  Blood lipid parameters 
Blood lipid parameters of subjects including; total cholesterol, triglyceride, HDL and LDL 
cholesterol, total/HDL cholesterol ratio, Apo A and Apo B are presented in this section. 
Blood lipid parameters of the subjects at baseline are shown in Table 5-3-1. The ANOVA 
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did not show any statistically significant difference among the three groups for blood lipid 
parameters at baseline. 
 
Table 5-3-1.  Means and standard deviations of blood lipid parameters of the subjects at 
baseline  
                    
                         Groups 
 
      Variables        
Conventional  
yoghurt  
Probiotic 
yoghurt  Control 
 
P- value 
Total Cholesterol 
(mg/dl)  173.90 ± 25.62 185.66 ± 23.86 184.38 ± 27.85 0.164 
Triglyceride (mg/dl) 78.97 ± 22.31 98.62 ± 39.81 95.83 ± 39.12 0.066 
HDL cholesterol 
(mg/dl) 50.70 ± 9.06 49.17 ± 9.95 49.17 ± 12.04 0.809 
LDL cholesterol 
(mg/dl) 101.03 ± 9.38 109.93 ± 17.92 109.86 ± 23.10 0.157 
Total /HDL cholesterol 3.51 ± 0.69 3.90 ± 0.88 3.92 ± 0.97 0.120 
Apo A (mg/dl) 144.70 ±18.65 144.55±21.67 144.72 ± 22.43 0.999 
Apo B (mg/dl) 87.80 ± 17.42 97.53 ± 21.08 96.53 ± 20.87 0.122 
 
 
The desirable level for total cholesterol is under 200 mg/dl.  Cholesterol levels of 200 to 240 
mg/dl are borderline high. As the results show, the mean concentrations of total cholesterol 
for the three groups were less than 200 mg/dl and they were not statistically significant. The 
mean concentrations of triglyceride for all groups were below 150 mg/dl, which is within 
the optimal level.  
Based on the NCEP (National Cholesterol Education Program), high density lipoprotein 
cholesterol less than 50 mg/dl for women is low and is considered a risk factor for heart 
disease.  HDL cholesterol values above 60 mg/dl are optimal and are considered to offer 
some protection against coronary heart disease. The mean concentration of HDL cholesterol 
in the present study was more than 50 mg/dl. There were no differences among the three 
groups in HDL cholesterol concentration. The value less than 100 mg/dl implies a desirable 
level of LDL cholesterol. The values between 100-129mg/dl are near optimal and values 
between 130-159 mg/dl are borderline high. The mean concentrations of LDL cholesterol 
for the three groups were near the optimal level.  
 65  
Based on the NCEP (2005) the optimum ratio for the total to HDL cholesterol is less than 
3.5, and ratio less than 4.0 is considered as low risk for women. The mean values for total 
cholesterol to HDL cholesterol ratio for the three groups were between 3.5 and 4.0.  The 
ratio increases when the total cholesterol increases and HDL cholesterol decreases. Low 
ratio shows lower risk of heart attack, while high rate indicates higher risk.  
The mean concentrations of Apo A, which manifests anti-atherogenic high density 
lipoprotein (HDL) particles, and Apo B, which reflects the number of potentially 
atherogenic lipoprotein particles, were within the normal range (80-175mg/dl and 45-
120mg/dl for women, respectively). High Apo B to Apo A ratio indicates increased risk of 
CVD. The risk for all three groups is less than 0.8, which could be considered as a 
protective factor for CVD. Results of statistical tests for each lipid parameter of the subjects 
are presented and explained separately below.  
 
5-3-1  Cholesterol 
Changes in the mean serum cholesterol concentration of the subjects during the course of 
the study are shown in Table 5-3-1-1. There were no statistically significant changes in total 
cholesterol concentration between baseline, third and sixth weeks of the study for any 
group. The cholesterol concentration decreased by 4.07% after six weeks in the probiotic 
yoghurt group, compared to 2.83% for the conventional yoghurt group. Though there were 
positive changes in both yoghurt groups, the results were not statistically significant within a 
single group. There was a 3.79% increase in the control group. 
 
Table 5-3-1-1   Means and standard deviations of blood total cholesterol during the study in 
each study group 
 
                         Intervals 
 
Variable      |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
P- 
value 
Deviation 
differenceª 
(%) 
Total 
Cholesterol 
(mg/dl) 
Conventional 
yoghurt 173.90±25.62 173.17±29.01 168.97±22.26 0.727 -2.83 
Probiotic 
yoghurt 185.66±23.86 184.41±27.98 178.10±25.42 0.493 -4.07 
Control 184.38±27.85 185.07±33.86 191.38±36.13 0.671 3.79 
ª- percentage of change between baseline and 6th week  
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In Table 5-3-1-2 the differences in mean values between T1 and T3 interval are presented. 
The differences between baseline means and sixth week means for cholesterol were 
statistically significant among the three groups (P=0.001). There was a decrease in both 
probiotic and conventional yoghurt consuming groups and an increase in the control group. 
The decrease was greater for the probiotic yoghurt (P<0.005) than the conventional yoghurt 
group (P<0.05). 
 
Table 5-3-1-2   Differences between baseline (T1) mean and 6th week (T3) mean of blood 
cholesterol for the three groups  
                                   
                                        Intervals 
Variable           |   Groups 
T1-T3 
(mean ± SD) P value 
Total 
Cholesterol 
(mg/dl) 
Conventional 
yoghurt -4.93 ± 13.74* 
0.001 Probiotic yoghurt -7.56 ± 12.83** 
Control 7.00 ± 19.85 
* P<0.05 vs. control,   ** P<0.005 vs. control 
 
 
 
The result of multiple comparisons for the three groups by Bonferroni post-hoc test is 
presented in Table 5-3-1-3.  The decrease in mean cholesterol concentrations were 
statistically significant for both conventional and probiotic groups, compared to the control 
group, respectively, P<0.014 and P<0.002.  
 
Table 5-3-1-3   Multiple comparisons of differences between baseline (T1) mean and 6th 
week (T3) mean of blood cholesterol among the three groups 
                                                      
                                                       Intervals 
Variable         |   Groups 
T1-T3 
(mean ± SE) P value 
Cholesterol 
(mg/dl) 
Conventional 
yoghurt 
Probiotic 
yoghurt -2.61 ± 4.10 1.000 
Control 
 11.93 ± 4.10* 0.014 
Probiotic 
yoghurt 
Conventional 
yoghurt 2.61 ± 4.10 1.000 
Control 
 14.55 ± 4.14* 0.002 
Control 
Conventional 
yoghurt -11.93 ± 4.10* 0.014 
Probiotic 
yoghurt -14.55 ± 4.14* 0.002 
* The mean difference is significant at the 0.05 level. 
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5-3-2  Triglyceride  
The means and standard deviations of triglyceride throughout the study are presented below 
(Table 5-3-2-1).  The mean concentration of triglyceride increased in the conventional 
yoghurt group by 3.62% and by 7.13% in the control group. There was a 0.17% decrease in 
the probiotic yoghurt group. Even though there was an increase in the mean values for 
control and conventional yoghurt groups after six weeks, the ANOVA did not show 
statistically significant change throughout the study at the three intervals for any group.  
   
Table 5-3-2-1    Means and standard deviations of triglyceride during the study in each 
study group 
                                            
                       Intervals      
 
Variable       |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
Triglyceride 
(mg/dl ) 
Conventional 
yoghurt 78.97±22.31 81.87±19.73 81.83±20.84 0.828 3.62 
Probiotic 
yoghurt 98.62±39.82 100.59±38.07 98.45±35.98 0.972 -0.17 
Control 95.83±39.12 100.45±31.88 102.66±33.91 0.752 7.13 
 
 
 
 
Comparing the differences between baseline means and sixth week means of triglyceride 
among the three groups did not show any significant difference (Table 5-3-2-2). The 
increase in the control group was more than twice the increase in the conventional yoghurt 
group. 
 
Table 5-3-2-2    Differences between baseline (T1) mean and 6th week (T3) mean of 
triglyceride for the three groups  
                             
                                      Interval 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
Triglyceride 
(mg/dl ) 
Conventional 
yoghurt 2.87 ± 11.70 
0.423 Probiotic yoghurt -0.17 ± 26.56 
Control 6.83 ± 20.03 
 
 68  
5-3-3  HDL cholesterol 
The HDL cholesterol concentrations of the three groups at the three intervals of the study 
are presented in Table 5-3-3-1. There were improvements in HDL cholesterol 
concentrations in both yoghurt consuming groups.  The highest increase in means from T1 
to T3 was in the probiotic yoghurt consuming group - by 8.76%. The increase in the 
conventional yoghurt group was 5.18%. There was a decrease by 0.77% in the control 
group. But, by conducting the ANOVA, changes in HDL cholesterol concentration during 
the course of the study within a group were shown to be not significant for any group. 
 
Table 5-3-3-1   Means and standard deviations of HDL cholesterol during the study in each 
study group 
                         
                          Intervals      
 
Variable      |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
HDL 
Cholesterol 
(mg/dl) 
Conventional 
yoghurt 50.70±9.06 54.43±8.25 53.33±8.88 0.241 5.18 
Probiotic 
yoghurt 49.17±9.95 52.97±8.13 53.48±9.26 0.153 8.76 
Control 49.17±12.04 50.66±13.40 48.79±12.44 0.839 -0.77 
 
 
 
The difference between baseline mean and 6th week mean concentrations of HDL 
cholesterol is shown in Table 5-3-3-2. There was an improvement in HDL cholesterol 
concentration in both yoghurt consuming groups. The improvement in the probiotic yoghurt 
group was higher than the conventional yoghurt group. The ANOVA showed statistically 
significant differences among the three groups (P<0.05).  
Table 5-3-3-2   Differences between baseline (T1) mean and 6th week (T3) mean of HDL 
cholesterol for the three groups  
                            Interval 
 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
HDL 
Cholesterol 
(mg/dl) 
Conventional 
yoghurt 2.63 ± 6.65 
0.011 Probiotic yoghurt 4.31 ± 5.70* 
Control -0.38 ± 5.11 
* P<0.05 vs. control  
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The multiple comparisons between the groups showed that the increase in mean 
concentration of HDL cholesterol for the probiotic yoghurt group was statistically 
significant, compared to the control group (P=0.009). (Table 5-3-3-3) The differences 
between the probiotic and the conventional yoghurt groups, as wells as differences between 
the conventional yoghurt and the control groups were not statistically significant.  
 
Table 5-3-3-3    Multiple comparisons of differences between baseline (T1) mean and 6th 
week (T3) mean of HDL cholesterol among the three groups 
 
                                                             Interval   
Variable          |   Groups 
T1-T3 
(mean ± SE) P value 
HDL 
Cholesterol 
(mg/dl 
Conventional 
yoghurt 
Probiotic 
yoghurt 1.68 ± 1.53 0.827 
Control 
 -3.01 ± 1.53 0.156 
Probiotic 
yoghurt 
Conventional 
yoghurt -1.68 ± 1.53 0.827 
Control 
 -4.69 ± 1.54* 0.009 
Control 
Conventional 
yoghurt 3.01 ± 1.52 0.156 
Probiotic 
yoghurt 4.69 ± 1.54* 0.009 
* The mean difference is significant at the 0.05 level. 
 
 
 
 
 
5-3-4  LDL cholesterol 
Low Density lipoprotein cholesterol concentration decreased by 1.14% in the conventional 
yoghurt group and by1.97% in the probiotic yoghurt group after 6 week intervention 
compared to the baseline values (Table 5-3-4-1). There was a 3.13% increase in LDL 
cholesterol concentration in the control group. The mean concentration of LDL cholesterol 
showed an ascending trend in the third week of intervention for the both yoghurt groups 
followed by a decrease in the sixth week. The ANOVA did not show any statistically 
significant change for LDL cholesterol concentration from baseline to third and sixth week 
of the study for any group.  
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Table 5-3-4-1   Means and standard deviations of LDL cholesterol during the study in each 
study group 
                         
                     Intervals 
 
Variable  |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
LDL-C 
 (mg/dl) 
Conventional 
yoghurt 101.03±19.38 103.07±21.86 99.87±19.16 0.825 -1.14 
Probiotic 
yoghurt 109.93±17.92 110.03±20.69 107.76±20.70 0.885 -1.97 
Control 109.86±23.10 113.31±24.29 113.03±24.21 0.830 3.13 
 
   
  
 
The differences between baseline and sixth week concentrations of LDL cholesterol showed 
improvement in values for the probiotic and the conventional yoghurt groups while there 
was an increase in the control group (Table 5-3-4-2). The differences between baseline and 
sixth week concentrations of LDL cholesterol were not statistically significant among the 
three groups. 
 
Table 5-3-4-2   Differences between baseline (T1) mean and 6th week (T3) mean of LDL 
cholesterol for the three groups  
                             
                                       Interval 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
LDL-C 
 (mg/dl) 
Conventional 
yoghurt -1.17 ± 9.36 
0.243 Probiotic yoghurt -2.17 ± 11.27 
Control 3.17 ± 16.66 
 
 
 
 
5-3-5  Total to HDL cholesterol ratio 
The total cholesterol to HDL cholesterol ratio helps to predict an individual's risk of 
developing atherosclerosis. High ratios indicate higher risks of CVD, low ratios indicate 
lower risks.  According to American Heart Association (AHA) recommendations, for 
women, a ratio of less than 4.0 is considered low risk and a ratio less than 5.0 is considered 
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average risk. The ratio was less than 4.0 for all groups, except for the control group at the 
third interval (4.16). 
 
Total cholesterol to HDL cholesterol ratio for the three groups at the three intervals is 
presented below (Table 5-3-5-1).  After six week intervention, there was a 12.56% decrease 
in total cholesterol to HDL cholesterol ratio in the probiotic yoghurt group and 7.69% 
decrease in the conventional yoghurt group. There was a 6.12% increase in the control 
group.  The improvement in the total cholesterol to HDL cholesterol ratio was twice as 
much in the probiotic yoghurt group compared to the conventional yoghurt group. The 
ANOVA did not show any statistically significant differences among the three intervals of 
the study within a group. The improvement that was observed in total cholesterol to HDL 
cholesterol ratio in both yoghurt consuming groups is due to the decrease in total cholesterol 
concentration and the increase in HDL cholesterol concentration in both yoghurt consuming 
groups.  
 
Table 5-3-5-1   Means and standard deviations of total/ HDL cholesterol ratio during the 
study in each study group 
                         
                           Intervals 
 
Variable        | Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
Total/HDL- 
Cholesterol 
  
Conventional 
yoghurt 3.51 ± 0.69 3.23±0.65 3.24±0.62 0.183 -7.69 
Probiotic 
yoghurt 3.90 ± 0.88 3.55±0.76 3.41±0.73 0.058 -12.56 
Control 3.92 ± 0.97 3.83±1.38 4.16±1.41 0.592 6.12 
 
 
 
 
The differences between baseline and 6th week mean concentrations of total to HDL 
cholesterol ratio were statistically significant among the three groups (P<000). (Table 5-3-5-
2) The improvement in the ratio was significant for the probiotic yoghurt group at P<0.001 
and for the conventional yoghurt group at P<0.05 compared to the control group.  
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Table 5-3-5-2    Differences between baseline (T1) mean and 6th week (T3) mean of total/ 
HDL cholesterol ratio for the three groups  
                            Interval 
 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
Total/HDL- 
Cholesterol 
  
Conventional 
yoghurt -0.27 ± 0.44* 
0.0001 Probiotic yoghurt -0.49 ± 0.57** 
Control 0.24 ± 0.77 
* P<0.05 vs control ,   **  P<0.001 vs control 
 
 
Multiple comparisons of the groups by Bonferroni showed significant increases in the ratio 
for both conventional yoghurt (P<0.006) and probiotic yoghurt groups (P<0.0001) compared 
to the control (Table 5-3-5-3). 
 
Table 5-3-5-3    Multiple comparisons of differences between baseline (T1) mean and 6th 
week (T3) mean of total/ HDL cholesterol among the three groups 
                                                                 Interval     
Variable             |   Groups 
T1-T3 
(mean ± SE) P value 
Total/HDL  
Cholesterol 
  
Conventional 
yoghurt 
Probiotic 
yoghurt -0.22 ± 0.16 .483 
Control 
 0.51 ± 0.16* .006 
Probiotic 
yoghurt 
Conventional 
yoghurt 0.22 ± 0.16 .483 
Control 
 0.73 ± 0.16* .000 
Control 
Conventional 
yoghurt -0.51 ± 0.156* .006 
Probiotic 
yoghurt -0.73 ± 0.16* .000 
* The mean difference is significant at the 0.05 level. 
 
 
 
 
 
5-3-6  Apolipoprotein A 
Apolipoprotein A values for each study group throughout the intervention are presented in 
Table 5-3-6-1.  Comparing the mean concentrations of Apo A at the three intervals by 
carrying out the ANOVA, did not show any statistically significant changes during the study 
for any group. There was an ascending trend in Apo A concentrations within the three 
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groups. The highest increase was in the probiotic yoghurt group by 5.61% followed by 
conventional yoghurt by 3.15%.  
Epidemiological studies have shown that plasma Apo A concentrations like those of HDL 
cholesterol are inversely related to the CVD (Walldius and Jungner, 2004). Apolipoprotein 
A is the main apolipoprotein in HDL cholesterol. The trend that was observed in the change 
in HDL cholesterol concentration in both yoghurt groups throughout the study is similar to 
what was observed for Apolipoprotein A. There was an improvement in HDL cholesterol 
concentration in both yoghurt groups, with a higher increase in the probiotic yoghurt group. 
Here, too, there was an increase in Apolipoprotein A in both yoghurt groups, with the 
highest increase in the probiotic yoghurt group.  
Table 5-3-6-1   Means and standard deviations of Apo A during the study in each study 
group 
                       Intervals 
               
Variable|   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
ApoA 
(mg/dl) 
Conventional 
yoghurt 144.70±18.65 151.30±21.27 149.27±20.01 0.428 3.15 
Probiotic 
yoghurt 144.55±21.67 152.00±19.53 152.66±20.72 0.258 5.61 
Control 144.72±22.43 147.00±19.76 146.70±20.79 0.906 1.36 
 
 
The ANOVA showed no statistically significant differences between baseline and sixth 
week mean concentrations of Apo A among the three groups, as illustrated in Table 5-3-6-2. 
The highest increase in Apo A concentration was observed in the probiotic yoghurt group 
followed by the conventional yoghurt group. 
 
Table 5-3-6-2   Differences between baseline (T1) mean and 6th week (T3) mean of Apo A 
among the three groups  
                             
                                         Interval 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
 
Apo A 
(mg/dl) 
Conventional 
yoghurt 4.57 ± 16.33 
0.307 
 
Probiotic 
yoghurt 8.10 ± 16.85 
Control 1.98 ± 11.68 
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5-3-7  Apolipoprotein B 
The means and standard deviations of Apolipoprotein B at the three intervals of the study 
for each study group are demonstrated in Table 5-3-7-1. The values were almost constant in 
both of the yoghurt groups, but there was an ascending trend in the control group. The 
changes in mean values at the three intervals were not statistically significant for any group 
(Table 5-3-7-1). 
Apolipoprotein B is the primary Apolipoprotein of low density lipoprotein cholesterol 
which carries cholesterol to tissues. Although LDL cholesterol is commonly used to assess 
CVD risk, Apo B may better reflect the risk. LDL cholesterol levels can be inaccurate in 
individuals with kidney and liver diseases, high triglyceride, and diabetes mellitus (Walldius 
and Jungner, 2004). In individuals who have normal cholesterol and triglyceride levels, Apo 
B assessment can identify those at higher risk. This is because it identifies the risk-
increasing small and dense LDL particles. 
 
Table 5-3-7-1   Means and standard deviations of Apo B during the study in each study 
group 
                         
                      Intervals 
 
Variable   |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
Apo B 
(mg/dl) 
Conventional 
yoghurt 87.80 ± 17.42 89.95±21.65 87.67±19.11 0.879 -0.15 
Probiotic 
yoghurt 97.53 ± 21.08 96.62±17.65 97.43±19.61 0.981 -0.10 
Control 96.53 ± 20.87 98.61±20.75 99.54±20.77 0.854 3.12 
  
An elevated Apo B to Apo A ratio could be a risk factor for CVD. The ratio less than 0.8 are 
associated with lower risk of CVD. The Apo B to Apo A ratio in the three intervals and in 
the three groups was less than 0.7.  
 
The differences between baseline and 6th week mean values of Apo B concentrations are 
presented in Table 5-3-7-2. There was a decrease for conventional and probiotic yoghurt 
group and increase in the control group. There were no statistically significant differences 
among the three groups.  
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Table 5-3-7-2   Differences between baseline (T1) mean and 6th week (T3) mean of Apo B 
among the three groups  
                                  Interval 
 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
 
Apo B 
(mg/dl) 
Conventional 
yoghurt -0.13 ± 9.75 
0.456 Probiotic yoghurt -0.10 ± 12.21 
Control 3.01 ± 10.70 
 
 
 
Table 5-3-7-3 shows the correlation between mean differences of total/HDL cholesterol 
ratio (T1 - T3) and mean differences (T1 - T3) of total cholesterol, and HDL cholesterol in 
the three groups. There was a positive and significant correlation between mean difference 
of total/HDL cholesterol ratio and mean difference of total cholesterol in both probiotic and 
control groups (P<0.05 and P<0.01). The correlation was negative and significant for HDL 
cholesterol mean differences in all three groups (P<0.01). 
 
Table 5-3-7-3   Correlation between mean differences (T1-T3) of total/HDL cholesterol 
ratio and lipid parameters in the three groups  
                                          
                                                              Correlation 
Variables                    |   Groups 
r P 
Total cholesterol 
mean difference  
(T1-T3) 
Conventional yoghurt 0.333 NS* 
Probiotic yoghurt 0.404 <0.05 
Control 0.611 <0.01 
HDL cholesterol 
mean difference  
(T1-T3) 
Conventional yoghurt -0.645 <0.01 
Probiotic yoghurt -0.764 <0.01 
Control -0.670 <0.01 
NS: not significant 
 
 
5-3-8  Summary of results for blood lipid parameters 
There were no statistically significant differences among the three groups in blood lipid 
parameters at baseline. There were no statistically significant differences throughout the 
study for lipid parameters within any group. Only in probiotic yoghurt group was the 
decline in total/HDL cholesterol ratio of 12.56% (P=0.058).  
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Comparing the mean differences between baseline and six week interval for triglyceride, 
LDL cholesterol, Apo A and Apo B showed no statistically significant differences among 
the three groups. For cholesterol, the differences were significant for both conventional and 
probiotic yoghurt groups at P<0.05 and P<0.005, respectively.  
For total to HDL cholesterol ratio the differences were also significant for both conventional 
and probiotic yoghurt groups at P<0.05 and P<0.001 respectively. The differences in mean 
concentrations of HDL cholesterol were significant for probiotic yoghurt group only (P 
<0.01). 
There was a positive and significant correlation between mean difference of total/HDL 
cholesterol ratio and mean difference of total cholesterol in both probiotic and control 
groups (P<0.05 and P<0.01).  The correlation was negative and significant for HDL 
cholesterol mean differences in all three groups (P<0.01). 
 
 
5-4  Oxidative stress parameters 
Means and standard deviations of total antioxidant capacity (TAC), oxidized LDL, and 
malondialdehyde (MDA) at baseline are presented in Table 5-4-1.  The ANOVA was 
applied to identify any differences in total antioxidant capacity, and oxidized LDL, among 
the three groups at baseline. Kolmogorov-Smirnov test was conducted.  The distribution of 
MDA was not normal. Naperian logarithm (i.e., the logarithm to the base e) was applied to 
convert MDA values to normal distribution. The ANOVA test did not show any statistically 
significant difference among the three groups at baseline for any of these parameters.  
 
Table 5-4-1   Means and standard deviations of blood oxidant and antioxidant parameters of 
subjects at baseline 
                    
                         Groups 
 
      Variables        
Conventional  
yoghurt  
Probiotic 
yoghurt  Control 
 
P- value 
TAC (mmol/l) 3.76 ± 0.28 3.74 ± 0.30 3.62 ± 0.35 0.182 
Oxidized LDL (U/l) 72.80±21.66 81.56±21.65 84.89±20.17 0.082 
MDA (nmol/ml) ª 2.49 ± 1.23 2.61 ± 1.20 2.65 ± 1.23 0.453 
ª Geometric mean is presented for MDA 
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5-4-1  Total Antioxidant Capacity (TAC) 
Means and standard deviations of TAC throughout the study for the three groups are 
presented in Table 5-4-1-1. To identify any change throughout the study at the three 
intervals, the ANOVA was used. The decreases of TAC values in the conventional and the 
probiotic yoghurt groups at third (T2) and sixth week (T3) of study were statistically 
significant at P<0.0001, compared to baseline values. There was a 14.36% decrease in TAC 
values for the conventional yoghurt group, and a 10.42% decrease in the probiotic yoghurt 
group. The decrease for the control group was 5.80%, which was half the value for the 
probiotic yoghurt and one third of the value for the conventional yoghurt. 
 
Table 5-4-1-1   Means and standard deviations of TAC during the study for the three groups 
                                          
                         Intervals 
Variable  |  Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) P- value 
Deviation 
difference 
(%) 
TAC 
(mmol/l)  
Conventional 
yoghurt 3.76 ± 0.28 3.45±0.41
a 3.23±0.41b 0.0001 -14.36 
Probiotic 
yoghurt 3.74 ± 0.30 3.51±0.35
c 3.36±0.37 b 0.0001 -10.42 
No yoghurt 3.62 ± 0.35 3.53 ± 0.30 3.41± 0.36 0.064 -5.80 
a   P<0.01 vs. baseline ,  b P<0.0001 vs. baseline,  c  P<0.05 vs. baseline  
 
  
 
The difference between baseline and sixth week means for each group is presented in Table 
5-4-1-2. The ANOVA showed statistically significant difference between baseline and sixth 
week means for the conventional yoghurt group compared to the control group. (P=0.002) 
 
Table 5-4-1-2   Differences between baseline (T1) mean and 6th week (T3) mean of TAC 
for the three groups  
                             
                                      Interval 
  Variable         |   Groups 
T1-T3 
 (mean ± SD) P value 
 
TAC 
(mmol/l)  
Conventional 
yoghurt -0.54 ± 0.36* 
0.002 Probiotic yoghurt -0.39 ± 0.30 
Control -0.21 ± 0.37 
* P=0.001 vs. control 
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Multiple comparisons of mean differences between T1 and T3 intervals, by conducting 
Bonferroni post-hoc test, showed significant difference between the conventional yoghurt 
and the control groups (P=0.001). (Table 5-4-1-3) 
 
Table 5-4-1-3    Multiple comparisons of difference between baseline (T1) mean and 6th 
week (T3) mean of TAC for the three groups 
 
                                                Intervals 
Variable           |   Groups 
T1-T3 
(mean ± SE) P value 
TAC 
(mmol/l ) 
Conventional 
yoghurt 
Probiotic 
yoghurt 0.15 ± 0.09 0.292 
Control 
 0.33± 0.09* 0.001 
Probiotic 
yoghurt 
Conventional 
yoghurt -0.15 ± 0.09 0.292 
Control 
 0.17 ± 0.09 0.166 
Control 
Conventional 
yoghurt -0.33 ± 0.09* 0.001 
Probiotic 
yoghurt -0.17 ± 0.09 0.166 
* The mean difference is significant at the 0.05 level. 
 
 
5-4-2  Oxidized LDL 
The means and standard deviations of oxidized LDL during the study are illustrated below 
(Table 5-4-2-1). There was a 3.71% increase in oxidized LDL in the probiotic yoghurt 
group, and a 2.18% increase in the conventional yoghurt group after 6-week intervention. 
There was a 0.73% decrease in the control group. Although there was an ascending trend in 
oxidized LDL in both yoghurt groups, the ANOVA did not show any statistically significant 
differences in oxidized LDL values in the three intervals of the study in any group.  
 
Table 5-4-2-1    Means and standard deviations of oxidized LDL during the study for the 
three groups 
                        Interval 
                          
Variable  |  Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
 
P- 
value 
Deviation 
difference 
(%) 
Oxidized 
LDL 
(U/l) 
Conventional 
yoghurt 72.80±21.66 73.86±23.78 74.39±23.64 0.963 2.18 
Probiotic 
yoghurt 81.56±21.65 83.15±23.20 84.59±23.94 0.882 3.71 
Control 84.89±20.17 82.98±21.73 84.27±20.80 0.939 -0.73 
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The ANOVA did not show any difference among the three groups in terms of difference 
between baseline (T1) and sixth week (T3) mean concentration of oxidized LDL (Table 5-4-
2-2). The highest increase in the oxidized LDL value was in the probiotic yoghurt group.  
 
Table 5-4-2-2   Differences between baseline (T1) mean and 6th week (T3) mean of 
oxidized LDL for the three groups  
                            Interval 
 
Variable           |   Groups 
T1-T3 
 (mean ± SD) P value 
Oxidized 
LDL (U/l) 
Conventional 
yoghurt 1.60 ± 8.42 
0.328 Probiotic yoghurt 3.02 ± 9.31 
Control -0.61± 10.06 
 
 
5-4-3  Malondialdehyde (MDA) 
The distribution of MDA was not normal; a Naperian log transformation of MDA values 
was performed to make data fit the normal distribution. To identify any differences in MDA 
values in the three intervals, the ANOVA was applied. Table 5-4-3-1 shows the geometric 
means of MDA, at the three intervals, for each study group.  
There was a 4.2% increase in MDA mean values in the probiotic yoghurt group and a 2.40% 
increase in the conventional yoghurt group, after six weeks. In the control group a 5.28% 
decrease in the MDA mean values was observed. The ANOVA did not show any significant 
differences in the intervals of the study for MDA in any group. 
 
Table 5-4-3-1    Geometric means and standard deviations of MDA during the study for the 
three groups  
                        Intervals  
                                         
Variable  |   Groups 
Baseline 
(T1) 
3rd  week 
(T2) 
6th  week 
(T3) 
P- 
value 
Deviation 
difference 
(%) 
MDA 
(nmol/ml) 
Conventional 
yoghurt 2.50 ± 1.23 2.50 ± 1.21 2.55 ± 1.24 0.898 2.40 
Probiotic 
yoghurt 2.62 ± 1.20 2.58 ± 1.27 2.72 ±1.22 0.567 4.20 
Control 2.66 ± 1.23 2.49 ± 1.24 2.52 ± 1.27 0.511 -5.28 
 
 
 
 80  
Differences between baseline (T1) and sixth week (T3) geometric means of MDA for each 
group are presented in Table 5-4-3-2. The ANOVA showed statistically significant 
difference in geometric means of MDA among the three groups. The difference was only 
significant for the probiotic yoghurt group compared to the control group (P=0.030). 
 
Table 5-4-3-2   Differences between baseline (T1) and 6th week (T3) geometric mean of 
MDA for the three groups 
                            Interval 
 
Variable           |   Groups 
T1-T3 
(mean ± SD) P value 
MDA 
(nmol/ml) 
 
Conventional 
yoghurt 0.98 ± 1.13 
0.030 Probiotic yoghurt 0.96 ± 1.14* 
Control -1.05 ± 1.17 
* P<0.05 vs. control 
 
 
Multiple comparisons of three groups showed significant differences in MDA values for the 
probiotic yoghurt group compared to the control group (P=0.038) (Table 5-4-3-3). 
 
Table 5-4-3-3   Multiple comparisons of differences between baseline (T1) and 6th week 
(T3) geometric means of MDA for the three groups 
 
                                                Intervals 
Variable           |   Groups 
T1-T3 
(mean ± SE) P value 
MDA 
(nmol/ml) 
 
Conventional 
yoghurt 
Probiotic 
yoghurt 
1.02 ± 1.04 1.000 
Control 
 
0.92 ± 1.04 0.125 
Probiotic 
yoghurt 
Conventional 
yoghurt 
0.98 ± 1.04 1.000 
Control 
 
0.91 ± 1.04* 0.038 
Control 
Conventional 
yoghurt 
1.08 ± 1.04 0.125 
Probiotic 
yoghurt 
1.10 ± 1.04* 0.038 
* The mean difference is significant at the 0.05 level 
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5-4-4  Summary of results for oxidant and antioxidant parameters 
The ANOVA results showed no statistically significant differences among the three groups 
at baseline for TAC, oxidized LDL, and MDA concentrations in the blood.  
TAC was significantly lower in third week (T2) and sixth week (T3) of the study, in both 
conventional (T2<T1; P<0.01 & T3<T1; P<0.0001) and probiotic yoghurt groups (T2<T1; 
P<0.05 & T3<T1; P<0.0001) compared to the control group. The ANOVA also, showed 
statistically significant differences between baseline and sixth week mean values of TAC for 
the conventional yoghurt group compared to the control group (P=0.002).  
There were no statistically significant differences in oxidized LDL among the three intervals 
of the study within any group. Neither were any differences between baseline and sixth 
week values among the three groups.  
For MDA, the differences between the three intervals were not statistically significant, but 
the changes between baseline and sixth week values were statistically higher for the 
probiotic group (P=0.038) compared to the control. 
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6    DISCUSSION 
6-1  General characteristics of the subjects 
There were no differences in age, body weight, height and BMI of the subjects at the 
beginning of the study among the three groups. The mean values for age, body weight and 
BMI tended to be a little higher in the probiotic yoghurt group compared to the other two 
groups, but they were not statistically significant. More importantly, comparing body 
weight and BMI of the three groups at the three intervals, showed almost no change in 
these parameters in any group. In fact, the P- values were either one or very close to one for 
all the three groups. The mean value for BMI was in normal range for three groups 
throughout the study. Changes in weight and BMI are a very important concern, especially 
in studies on lipid profile; changes in weight and BMI during the course of intervention can 
independently influence the results and can act as a confounding factor. 
 
One of the early studies on the effect of milk on cholesterol concentrations was done on the 
Maasai people in Africa (Mann and Spoerry, 1974). The study came to an end after 3 week 
instead of 4 week. The reason for this was the great quantity of milk drunk by the 
participants.  The researchers prompted subjects to exercise more. However, subjects did 
not implement any increase in their exercise and therefore put on weight.  In case of the 
Maasai tribe, even thought the subjects put on weight, there was a considerable reduction in 
cholesterol concentrations in both fermented milk consuming groups.  
 
In another trial on the effect of a fermented milk product GAIO on risk factors for 
cardiovascular diseases in obese and overweight subjects, when comparing all experimental 
groups, without adjustment for alterations in body weight, no statistically significant effect 
was seen in LDL cholesterol in the probiotic group. The reduction in LDL cholesterol 
(8.4%) and increase in fibrinogen happened in probiotic (GAIO) consuming group compared 
to the acidified milk consuming group, only after applying adjustment for body weight 
alteration (Agerholm-Larsen et al, 2000). 
 
6-2  Dietary intakes of the subjects 
In some studies, researchers gave the subject the probiotic bacteria in the form of a capsule. 
The reason for this was to simplify the distribution process and also, to do away with 
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obliging participants to alter their eating habits or eat research- connected foods. Adding 
dairy products to the food regime as a means of providing probiotics can change the dietary 
intakes of the subjects. As a result of this change, the energy, fat, and some other nutrient 
intakes of the subjects may be altered. The change in nutrient intakes can influence the 
results of a study and act as a confounding factor. Nevertheless a dairy product seems to be 
the most effective vehicle for giving probiotic bacteria to people. Most of the research that 
utilized fermented milk, in the form of yogurt or dairy products, showed an 
hypocholesrolemic influence (Agerback et al, 1995; Bertolami et al, 1999; Schaafsma et al, 
1998; Xiao et al, 2003). This is in comparison to the failure of placebo-controlled studies 
that fed non dairy food (Jahreis et al, 2002) or capsules to participants (Lewis and 
Burmeister, 2005; Greany et al, 2008). Controlling the energy and fat intake, therefore, is of 
great importance in such studies.  
 
Greany et al (Greany et al, 2004) conducted a study to assess the independent and synergetic 
impact of soy and probiotic bacteria on some lipid parameters in humans. The study was 
done on postmenopausal females, who were assembled into four intervention groups:  Of 
the four groups, two of them consumed soy protein (one soy protein alone, the other with 
probiotic capsules). The other two groups were given milk protein (again one of them milk 
protein alone, the other with probiotic capsules). The nutrient ingestion at baseline and 
during the soy and milk regime interval was compared. The evaluation indicated a reduction 
in the amount of fiber and protein consumed (P< 0.004 & P< 0.0001). On the other hand, no 
notable change was seen in the amount of energy or macronutrients consumed in their 
regime.  No adjustment was applied. According to the study, probiotics did not boost the 
effects of soy. Nor did it help to reduce cholesterol. 
 
In a trial conducted by Agerholm-Larsen et al (Agerholm-Larsen et al, 2000), four out of 
five groups were given yogurt with various strains of bacteria, whereas the remaining group 
was given placebos. The duration of the intervention was 8 weeks and subjects were 
required to fill out 7- day records of their food intake at the start and the end of the study. 
The weighted records did not show any difference in average energy consumption across 
the different groups. The same was true for macronutrient intake. Changes in intake of 
alcohol and carbohydrates from baseline to 8-week, however, were significant among the 
groups. The study stated that usual individual differences and multiple testing could 
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account for the dissimilarity seen between the groups. When statistically weight gain 
(changes) was controlled in the probiotic group, there was a reduction in LDL cholesterol.  
  
A cross-over study was conducted to examine the effect of yogurt with L.acidophilus on 
plasma cholesterol. Participants with elevated cholesterol levels had to take 200 ml 
fermented milk for the course of 3 weeks (Anderson and Gilliland, 1999). Participants were 
asked to maintain their normal diet for the course of the intervention. Also, they were 
required to fill out three-day diet records and turn them in at each interval and at the end of 
each fermented milk treatment.  No meaningful difference in terms of nutrient ingestion 
was shown in the mean dietary consumption (proteins, energy, carbohydrates, cholesterol, 
fatty acids and alcohol) between the groups or during the trial period. The results showed a 
reduction in cholesterol concentration in the probiotic consuming group.  
 
In a cross-over study by Fabian and Elmadfa (Fabian and Elmadfa, 2006), volunteers 
consumed 100 g/day conventional or probiotic yoghurt for 2 weeks and 200 g/day for 
another 2 weeks. Means for dietary intakes were calculated by 24 hour food records. There 
were no changes in dietary intakes within or between the tested groups throughout the 
investigation. Consumption of both conventional and probiotic yoghurts for 4 weeks had a 
positive effect on the lipid profile in the plasma of healthy women. 
 
There is a possibility that by introducing yoghurt to the diet of subjects, a change in fat 
intake or consequently weight gain may occur. We did not find any significant changes in 
energy, fat and relevant nutrient intakes within or among the groups during the study. At 
the three intervals (baseline, 3 week, 6 week) three-day dietary records were taken from 
each volunteer who was directed to write down the types and amounts of foods eaten. The 
amount of food eaten by each subjects was estimated from household measures and from 
photos of serving sizes. A nutritionist checked the participants’ dietary records in person 
upon their periodically visits to the Nutrition Department at TUMS Subjects were 
instructed to maintain their usual dietary habits throughout the experiment. Weekly follow 
ups were performed by phone. Monitoring the diets of the participants helped to avoid any 
changes in their diets. Furthermore, consumption of yoghurt is part of a dietary habit in 
Iran. Therefore, supplementing the yoghurt in the diet of the subjects did not cause a 
modification in their dietary habits.   
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6-3 The effects of probiotic yoghurt on blood lipid parameters 
 
Hypothesis: There are improvements in lipid profile parameters in probiotic and 
conventional yoghurt consuming groups compared to the control group. 
 
In the present study, at baseline, there were not statistically significant differences among 
the three groups in total cholesterol, triglyceride, HDL and LDL cholesterol, total/HDL 
cholesterol ratio, Apo A and Apo B concentrations.  
There were descending trends in total cholesterol and LDL cholesterol concentrations 
throughout the study in both conventional yoghurt (-2.83% and -1.14%) and probiotic 
yoghurt (-4.07% and -1.97%) groups. There was an ascending trend in HDL cholesterol 
concentration throughout the study in the conventional (5.18) and the probiotic (8.78) 
yoghurt consuming groups. An ascending trend was also seen in Apo-A concentration in 
both yoghurt groups. Despite all these alterations in lipid profile, there were no statistically 
significant differences within group for any of these parameters. The significant results were 
obtained only when mean differences (T1-T3) were compared among the three groups.  
 
Comparing changes in the mean differences (T1-T3) showed significant improvement in 
total cholesterol and total to HDL cholesterol ratio in both conventional and probiotic 
yoghurt groups compared to the control. The improvement in mean differences (T1-T3) of 
HDL cholesterol was only significant for the probiotic yoghurt consuming group compared 
to the control.  The positive and significant changes that were observed in this study were 
attributed to both the conventional and probiotic yoghurt groups. There were no differences 
between the two yoghurt consuming groups.  
 
The reason that we did not observe any significant improvement in lipid parameters within a 
group could be that our subjects in all three groups were healthy people and had low risk of 
cardiovascular disease.  As presented in the results section, all the subjects at baseline and 
throughout the study had HDL cholesterol values above 60 mg/dl. This could offer some 
protection against coronary heart disease. The optimum ratio for the total to HDL 
cholesterol is less than 3.5, and ratio less than 4.0 is considered as low risk for women. The 
mean values for total cholesterol to HDL cholesterol ratio for the three groups were between 
3.5 and 4.0. High Apo B to Apo A ratio indicates increased risk of CVD. The risk for all 
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three groups was less than 0.8, which could be considered as a protective factor for CVD. In 
addition, the dietary intakes of the subjects also could have protective effect. In the present 
study, the mean values for SFA, MUFA, and PUFA from total energy were between 10 to11 
percent in the three groups (Table 5-2-1). It is suggested that the polyunsaturated to 
saturated fatty acids ratio close to one could lower the risk of cardiovascular diseases. In the 
present study, at baseline, the P/S ratio was 1.03 for both yoghurt groups and 0.95 for the 
control group. The dietary intakes of the subjects, too, could have a protective effect and 
could be the reason that significant changes were not observed within a group. 
 
Consumption of fermented milk (yoghurt) could account for the reduction in cholesterol 
concentration in this study. Some early studies on fermented milk (FM) also showed 
hypocholesterolemic effect of these products on lipid plasma. Human studies on effect of 
fermented dairy products on cholesterolemia have been conducted since the 1970s. In an 
experiment in which 4 groups supplemented their diet with unpasteurized yoghurt, 
pasteurized yoghurt, or 2%-fat milk, or continued their regular diet for 3 months, 
cholesterol decreased by 9% in the group consuming unpasteurized yoghurt, after the first 
week of the intervention (Hepner et al, 1979). In the yoghurt consuming groups the 
decrease was 5%. The researchers concluded that a minor cholesterol lowering effect may 
possibly be contributed to milk. They also concluded that yoghurts (pasteurized and not 
pasteurized) had the same effect on levels of cholesterol.   
 
Harrison and Peat (Harrison and Peat, 1975) demonstrated that in comparison to the control 
formula, infant formula containing L. acidophilus caused lower serum cholesterol amounts.   
In a study by Agerbaek et al (Agerbaeck et al, 1995), examining the relationship between 
Enterococcum faecium fermented milk products plus two strains of S. thermophilus, on 
lipid profile; a meaningful decrease of 10 % in low density cholesterol was discovered after 
daily intake of fermented milk products for six weeks. This was in comparison to control 
group which consumed acidified milk. High density lipoprotein and triglyceride remained 
constant in the two groups. After a six-month trial, the decrease in low density lipoprotein 
level of the subjects was the same as that of those that took the placebo product. This shows 
the probable existence of cholesterol lowering effects in both low-fat and fermented milk 
(Richelsen et al, 1996).  
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In a study conducted by Schaafsma et al, (Schaafsma et al, 1998) in which for 21 days 
subjects consumed milk fermented with two strains of  L. acidophilus on a daily basis, a 
meaningful decrease  of 4.4 % in plasma cholesterol and a 5.4 % decrease in low density 
lipoprotein was observed. The yogurt consumed contained a percentage of fructo-
oligosaccharides (2.5 %). This could also have had an influence on level of plasma 
cholesterol. Concentrations of plasma high density lipid stayed unaffected. This was also 
true of triglyceride levels. 
 
In a different double blind study, conducted by Anderson and Gilliland (Anderson and 
Gilliland, 1999), which was cross over trial and used placebos, one group consumed 
fermented milk with L. acidophilus L1, while the other was given the placebo, both for 
duration of four weeks.  Within the first treatment period, a 3.2 percent reduction in plasma 
cholesterol levels was seen. During the second treatment period, neither of the groups 
showed any significant variation in their plasma cholesterol levels.  
 
Akalin et al (Akalin et al, 1997) carried out a study on mice to investigate the effect of 
acidophilus and dietary yogurt on lipid and triglyceride levels. Besides the control group, 
the other two groups were given either acidophilus or ordinary yogurt. There was a 
significant reduction of total cholesterol by 17% and low density lipoprotein levels by 33% 
in the acidophil group. However, the decrease in total cholesterol and low density 
lipoprotein cholesterol of respectively 7% and 11% in the ordinary yogurt group was not 
significant.  In neither group was there any change in low density lipoprotein and 
triglyceride levels. The trial showed that L. acidophilus was able to establish itself in the 
animal’s GI tract easier than the other strain. Compared to conventional yogurt, acidophilus 
yogurt was capable of decreasing plasma cholesterol levels with more success.   
 
The significant decrease in the mean difference of total to HDL cholesterol ratio in both 
yoghurt consuming groups in the present study could be the consequence of the decrease in 
total cholesterol level as well as the increase in HDL cholesterol concentration after 
consuming both conventional and probiotic yoghurts for 6 weeks. Kiessling et al (Kiessling 
et al, 2002) demonstrated that the intake of yogurt with 3.5% fat and cultures of L. lactis and 
S.thermophilus did not change the mean values of total or low density lipid cholesterol. This 
was also true for consumption of B. Longum 913, L. acidophilus 145, and 1% oligofructose 
enriched probiotic yogurt. Continued intake of these two yogurts for a twenty one week 
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period resulted in elevation of plasma high density lipoprotein. This in turn led to more 
favorable LDL to HDL ratios. The researchers proposed that cause of the increased high 
density lipoprotein concentrations could be the sphingolipids present in the high fat 
fermented milk.  
  
In a cross-over clinical study on women with normal cholesterol levels, effects of eating 
probiotic yoghurt with Lactobacillus casei subsp. casei or conventional yoghurt were 
compared (Fabian and Elmadfa, 2006).  There were a number of favorable changes in lipid 
levels of the participants, but no significant difference was seen in triglyceride, low density 
lipid, high density lipid, and total cholesterol levels between the probiotic and conventional 
yoghurt groups.  The researchers’ conclusion was that the change in lipid levels could 
probably be explained by the type and amount of fatty acids in the milk fat and the 
sphingolipids in the yoghurt.  
 
In the present study, too, the effects were observed in both yoghurt consuming groups 
compared to the control. There were no differences between the two yoghurt groups. 
Another explanation for the observed effects in both yoghurt groups in this study could be 
the sphingolipids in yoghurt and distribution of the milk fat (Kiessling et al, 2002; 
Samuelson et al, 2001; Fabian and Elmadfa, 2006; Vesper et al, 1999). The conventional 
and the probiotic yoghurts which were used in the present study contained 2.5% fat. 
Therefore, the sphingolipids in both yoghurts could have been similar. However, 
sphingolipids also can be found in cell membranes of bacteria which were higher in 
probiotic yoghurt.  A number of studies have demonstrated that sphingolipids can reduce 
LDL and total cholesterol, and are able to increase HDL cholesterol (Vesper et al, 1999; 
Kobayashi et al, 1997; Imaizumi et al, 1992). Other has demonstrated that sphingolipids are 
able to reduce the LDL/HDL ratio (Smedman et al, 1999). Complex sphingolipids and their 
derivatives products in the body, such as sphingosines and ceramides, are very bioactive 
substances that significantly impact cell regulation. Sphingolipids can be found in cell 
membranes, low density lipids, and compounds which contain high lipid. Cholesterol 
circulation and its movements from cellular tissues, and also its metabolism are affected by 
sphingolipids (Jian et al, 1997; Yancey et al, 1995; Zhao et al, 1996). So are its change to 
other products, such as bile and cholesterol esters (Boldin and Jonas, 1996).  HMG-CoA 
reductase regulation, is another cholesterol activities that sphingomyelin affects (Gupta and 
Rudney, 1991). Sphingolipids’ effect in lowering serum cholesterol has been demonstrated 
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in several long and short term studies on rats (Imaizumi et al, 1992; Kobayashi et al, 1997). 
The animals that were given semi-purified food enriched with sphingomyelin and 
glycosphingolipids, along with 4% soybean oil showed a 30% reduction in their serum total 
cholesterol, compared to rats that had 5% soybean oil. Their triglycerides showed no 
difference.  
 
Another possible explanation for the hypocholesterolemic effects in both the probiotic and 
conventional yoghurt consuming groups in the present study could be the fat distribution in 
milk.  Scientists have proposed that in different populations consumption of fatty acids or 
saturated fat may have a significant effect on increasing cholesterol levels and on mortality 
rate from  cardiovascular diseases (Artauld-Wild et al, 1993). However, studies done within 
a population have not always shown a significant association between consumption of high 
fat milk or butter fat and cardiovascular disease (Ascherio & Willett, 1995; Pietinen et al, 
1997). In epidemiological studies, it is hard to find meaningful association between fat 
intake and lipid profile in plasma within a population. This is despite the fact that significant 
correlation has been observed in some clinical trials between SFA and ApoB and lipid 
profile (Katan et al, 1995). Flaws in dietary measurements, genetic differences among the 
subjects in their reaction to changes in diet, differences in daily food consumption, and 
inappropriate sample size could all have contributed to this lack of agreement among study 
results. Yet another explanation could have to do with the intricate association that exists 
between lipid profile and food intake. 
 
Number of extensive investigations done on diet and serum lipids failed to demonstrate a 
meaningful correlation the fat consumed and plasma lipids (Glueck et al, 1982; Gordon et 
al, 1982; Schwartz et al, 1982).  In a study on children in Finland by Moilanen et al., a 
small, albeit weak, association was observed between Myristic Acid (C14:0) in plasma 
cholesterol esters and plasma cholesterol and Apo B levels (Moilanen et al, 1986).  Fatty 
acids such as (C12:0 and C14:0) in milk are believed by other researchers to be responsible 
for the elevation of high density lipids levels and the reduction in TC/HDL-C ratio 
(Samuelson  et al, 2001; Mensink  et al, 2003; Temme et al, 1996).  
 
A reverse meaningful association between short chain fatty acids in milk and plasma 
cholesterol was also observed in another study in older men. Such inverse correlation was 
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present between their waist measurements, body mass index, LDL/HDL ratios and milk 
(Smedman et al, 1999).  
  
In addition, in some studies in which the probiotic was given to the subject, not in the form 
of dairy products containing probiotics but rater in the form of capsules, the probiotic 
bacteria did not show cholesterol-lowering ability (Lewis and Burmeister, 2005; Greany et 
al, 2008). In a pilot study, subjects were given   L. acidophilus and L. bulgaricus pills for a 
duration of 16 weeks. This study was not placebo controlled. The results showed that the 
serum cholesterol had decreased in the test group.  In the second crossover study, with a 
double blind and randomized design, subjects with high cholesterol levels were selected 
(Lewis and Burmeister, 2005).  For six weeks the subjects had to consume freeze dried L. 
acidophilus or placebo capsules three times each day. The type of capsules volunteers had to 
consume was assigned randomly. No changes were noted in the serum lipids of the subjects, 
this is in spite of the in vitro capacity of L. acidophilus to decrease cholesterol.   
 
In a different study, but also using placebo, normocholesterolemic participants, were given 
lactobacillus acidophilus and bifidobacterium longum plus fructo- oligosaccharide probiotic 
tablets or placebo tablets. Subjects had to consume these tablets for two months after which 
the results showed that  consumption of the probiotic and placebo capsules had resulted in 
no change in plasma levels of total cholesterol and high and low density lipoprotein 
cholesterol. No change was seen in triglyceride levels as well (Greany et al, 2008). 
 
The above mentioned studies all support the idea that fermented milk is a suitable vehicle 
for feeding probiotics to individuals. Based on their research on Maasai tribe, Mann and 
Spoery asserted that there is a factor in milk that causes reduction in cholesterol levels. 
Therefore, the more milk consumption, the larger the drop in cholesterol level (Mann and 
Spoerry, 1974). They concluded that milk reduced cholesterol synthesis. This seems to be 
the general conclusion in other studies as well that milk, with whatever fat content, is 
effective in reducing plasma cholesterol levels (Buonopane et al, 1992; Golay et al, 1990; 
Sharpe et al, 1994). Different studies suggest different factors for this phenomenon. Most of 
the studies, however, have not been able to specifically confirm that particular component, 
such as riboflavin, IgG, hydroxyl-methyl glutarate, magnesium, or other compounds may be 
responsible for cholesterol lowering effect of milk or that it is the microflora in the GI tract 
that may be behind this effect.  
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The bacteria in fermented milk reduce lipid levels in the body through a variety of 
mechanisms. Taurine and glycine get conjugated with bile acids that hepatic cells create 
from cholesterol. As the conjugated acids pass through the small intestine, they are 
assimilated and led to the liver. But, as they are being reabsorbed, these acids face the 
intestine’s flora.  Bifidobacteri, lactobacilli, and other bacteria contained in fermented food 
hydrolyze the bile acids. Certain lactic acid bacteria strains, like L. acidophilus, are able to 
remove cholesterol from lab media and turn it into bile acids under anaerobic conditions and 
in the presence of bile (Gilliland, 1990; Delmi-Bouras, 2006). In human and animal trials, 
the reason for removal of cholesterol is that while they are in the large intestine, 
deconjugated bile acids do not get reabsorbed. They leave the body with urine and feces. 
This results in reduced recycling of bile acids and leads to an increase in production of new 
bile acids by the body.   
 
Gilliland et al showed that some strains of L. acidophilus grown with the presence of bile 
have shown to have the ability to change cholesterol metabolism (Gilliland et al, 1985). In 
their study, the amount of bile present in the environment did not go beyond that in human 
intestine. One may, therefore, conclude that this could also take place in vivo. The bacteria’s 
action, then, would leave little cholesterol to be absorbed into the blood. 
 
Bacteria in the large intestine are active in fermenting carbohydrates and other unabsorbed 
polysaccharides, as well as mucus, to create short chain fatty acids (Wolever et al, 1996). 
The production of cholesterol is probably affected by the relative amounts of butyrate, 
propionate, and acetate that are created by the bacteria (Venter et al, 1990). All substrates 
are involved in the production of acetate, but the quantity of propionate and butyrate is not 
constant. Recorded changes in short chain fatty acid production in the colon is evidence of 
the mentioned fermentation (Wong et al, 2006). In the present study, the SCFA production 
was not measured in the feces.  
 
The large intestine readily absorbs short chain fatty acids when they are in the gut. Then, the 
liver metabolizes them (Cummings and Macfarlane, 1997). In order to find out how much of 
the acetate that is created in the colon actually ends up in blood circulation, Wolever et al. 
studied the interaction between short chain fatty acids in the colon and in blood serum. Their 
study showed that combinations of sodium acetate or sodium propionate in the rectum 
elevated concentrations of both in the blood. Based on their findings, acetate causes an 
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increase in total cholesterol, and reduces fatty acids. They further concluded that propionate 
elevates blood glucose and reduces the cholesterol lowering response stimulated by acetate 
(Wolever et al, 1991).  
 
One may presume, therefore, that consumption of dairy products fermented with the proper 
strain of bacteria can lead to a lower cholesterol level in blood. This study showed that both 
yoghurt products had a positive effect on the lipid profile of the subjects. The modulation in 
lipid profiles in this study could be the results of different mechanisms that were discussed 
as well as the fatty acid distribution of the milk fat and the sphingolipids contained in the 
yoghurt.  
 
 
6-4  The effects of probiotic yoghurt on blood oxidant and 
antioxidant parameters 
Hypothesis: There is a decrease in malondialdehyde and oxidized LDL concentration and 
an increase in total antioxidant capacity in the probiotic and conventional yoghurt groups 
compared to the control group. 
 
The results of the present study showed that TAC decreased significantly in both the 
conventional and the probiotic yoghurt consuming groups compared to the control. The 
oxidized LDL and MDA concentrations showed ascending trends throughout the study in 
both yoghurt consuming groups, but changes were not statistically significant. 
Comparing the mean differences (T1-T3) among the three groups showed significant 
decrease for TAC in the conventional yoghurt group compared to the control and significant 
increase for MDA in the probiotic yoghurt group compared to the control.  
The significant changes on blood oxidant and antioxidant parameters are mainly attributed 
to both the conventional and the probiotic yoghurt groups compared to the control group. 
Similar to what was observed in lipid profile results, there was not any significant difference 
between the two yoghurt groups. 
 
There are very few studies specifically on the effect of probiotic yoghurt on antioxidant 
parameters in humans, and the results are contradictory. In an investigation by Kullisaar et 
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al (Kullisaar et al, 2003) intake of goat milk enriched with Lactobacillus fermentum ME-3, 
compared to ordinary goat milk, boosted long-term resistance of the lipoproteins to 
oxidation. It also reduced concentrations of peroxidized lipoproteins, oxidized low density 
lipoproteins, 8-isoprostanes and glutathione redox ratios. The study showed that the 
fermented goat milk increased total antioxidative activity.  
  
Kapila et al (Kapila et al, 2006) showed that the TBARS concentrations were lower in the 
low density lipoprotein fraction of blood serum in rats that were given fermented milk 
compared to those on a non fat milk diet. These findings show the hypocholesterolemic and 
antioxidative properties of Lactobacillus casei ssp. casei.  A study by Fabian and Elmadfa 
(Fabian and Elmadfa, 2007) demonstrated a meaningful drop in values of total antioxidant 
capacity of both conventional and Lactobacillus casei-enriched yoghurt consuming groups. 
The study also showed that malondialdehyde and conjugated dienes values in both groups 
increased. Although many other parameters were altered considerably as a result of the 
investigation, there were no meaningful differences between the conventional and probiotic 
groups.  
 
The results from the study by Fabian and Elmadfa (Fabian and Elmadfa, 2007) are somehow 
similar to the present study. In the present study, the observed effects were seen mainly in 
both yoghurt consuming groups for TAC concentration. Even though the mean difference 
(T1-T3) comparison showed significant results for MDA and TAC, in conventional and 
probiotic yoghurt consuming groups, respectively, those changes were significant only 
compared to the control group and not compared to the other yoghurt group. The alterations 
and trends observed in the antioxidant parameter and lipid peroxidation parameters indicate 
an increase in oxidative stress which could be due to the immune system stimulation caused 
by administration of both yoghurts.   
 
It has been demonstrated that intake of yoghurt and consumption of lactic acid bacteria 
stimulate the immune system. For years it was believed that yoghurt had properties that 
boosted the humans’ defense mechanisms against harmful elements. Yet, the specific 
components in yoghurt that were behind this action were not quite identified. It is suggested 
that yoghurt’s stimulating effect on the immune system come from the bacteria that live in 
it, but the mechanism through which this happens has not been quite identified. It is the 
compounds like peptidoglycan, teichoic acid, and polysaccharide in the walls of lactic acid 
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bacteria cells that have been demonstrated in various studies to be responsible for this action 
(Takahashi, et al 1993). Live or active lactic acid bacteria particles could stimulate both 
specific and nonspecific immune response. The immune stimulating activity of the bacteria 
in the intestine is to a large extent contingent upon their interaction with lymphoid cells in 
the lumen. As they are readily removed from the mucosa, the nonviable bacteria are 
supposedly a lot less effective antigens (Muscettola et al, 1994). A number of investigations, 
though, have demonstrated no difference, between live and dead in terms of their 
immunogenicity (Hatcher and Lambrecht, 1993). 
 
One of the key elements of peptidoglycan in cell of bacteria is Muramyl dipeptide (MDP).  
It is important in discharging IL-1. MDP does that through stimulation of Marophages. IL-1 
is necessary for production of IFN-  by lymphocytes. It was shown by Tufano et al (Tufano 
et al, 1991) that production of interlukins (IL-1, IL-4, IL-6) and TNF-  and IFN-  are 
induced by MDP.  In the case of interlukins MDP does this through monocytes and in the 
case IL-4 and IFN-  through lymphocytes. (Meydani and Ha, 2000)  
 
It should be mentioned, however, that other elements exist in the fermented milk or milk 
itself such as free fatty acids or peptides could stimulate the immune system, when yoghurt 
is consumed. These elements are not necessarily the bacterial part of the milk or FM, but 
they could be the parts which contain vitamins, minerals such as calcium, and proteins and 
are able to stimulate immune system. 
 
Conjugated linoleic acid (CLA), which is a linoleic acid derivative, can be found in higher 
amounts in yoghurt compared to the milk source of the yoghurt itself. Products obtained 
from mammals such as cattle, sheep and goat are the main contributors to the CLA in our 
food. It has been shown that a correlation exists between CLA in fat tissue and human milk 
on one hand and fat content in milk and its products on the other. (Jiang et al, 1999; Park et 
al, 1999) 
Increases in the amount of CLA in human adipose tissue were demonstrated to be linked to 
higher consumption levels of dairy fat (Jiang et al, 1999). This was also the case for 
increased CLA levels in human milk (Park et al, 1999).  CLA was stated to have the ability 
to stimulate the immune system and also to have anticarcinogenic qualities (Badinga and 
Greene, 2006). Certain CLA isomers have the capability to stop the manifestation of cyclins. 
In a study on cancer cells of the breast and colon, Kemp et al (Kemp et al, 2003) 
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demonstrated that this ability of CLA isomers can be the reason for the anticarcinogenic 
qualities of CLA. 
 
In research done on humans, it has been demonstrated that intake of yoghurt enhanced 
activity of phagocytes and NK cell and production of cytokine and antibody. In vitro studies 
on cells showed similar results, after exposure to lactic acid bacteria (Solis-Pereyra and 
Lemonnier, 1993; Aattouri and Lemonnier, 1997; Galdeano et al, 2007; Peng et al, 2007; 
Schiffrin et al, 1995). In a study by Perdigon et al on mice, it was demonstrated that feeding 
yoghurt and L. acidophilus and L. casei increased sIgA and sIgA-producing cells in the 
animals’ small intestine (Perdigon et al, 1995); The greater the dosage, the greater the effect. 
Puri et al. showed in their study that plasma IgA levels in mice that were given yoghurt were 
considerably higher than those in mice that were given milk. They suggested that the IgA 
that the B cells in the intestine produce gets into the blood and elevates plasma IgA levels 
(Puri et al, 1996).  
 
Administering L. casei by mouth had similar effects to that of probiotic yoghurt. It caused 
more sIgA to be available in the lumen. Perdigon et al. (Perdigon et al, 1991) suggested that 
this increase in sIgA level is a result of lactic acid bacteria’s effect on Peyers’ patches, 
which alter the ratios of CD4 and  CD8. Meyer et al showed in their investigation (Meyer et 
al, 2007) that consumption of Lactobacillus casei-enriched and conventional yoghurts led to 
an increase in TNF- . The normal yoghurt consuming group showed a considerably higher 
amount of interleukin (IL)-1beta, while the probiotic consuming group showed higher IFN-
. Intake of both yoghurt types boosted pro-inflammatory cytokine production.  
 
Matsuzuki and Chin found in their study that eating Lactobacillus casei strain Shirota 
boosts innate immunity through the activity of natural killer cells (Matsuzaki and Chin, 
2000). In their study on effects of probiotic supplements on healthy individuals, Christensen 
et al did not find any positive effect on immune response of their subjects (Christensen  et 
al, 2006). This was true even when high doses of B. animalis ssp. lactis BB-12 and L. 
paracasei ssp. paracasei were used.  
 
In a study, rats were fed L. acidophilus and L. casei-enriched Dahi. Peroxidation of lipids 
and formation of NO were reduced as a result. The probiotic Dahi preserved antioxidant 
compounds, like glutathione, and SOD, catalase and GPX effects (Yadav et al, 2008). 
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Consumption of Dahi led to reduction in total cholesterol and blood pressure in humans. It 
also resulted in a considerable increase in macrophage function. The results also 
demonstrated the unfavorable effect of cholesterol on the body’s immune function (Pawan 
et al, 2007). 
 
Eating fermented yoghurt enriched with Lactobacillus acidophilus and Bifidobacterium 
animalis subsp. lacti, for five weeks resulted in meaningful increase in phagocyte activity as 
compared with a group that was fed placebo. The two groups showed no difference, 
however, in oxidative or immune functions (Klein et al, 2008). 
 
Studies done on both humans and animals over the years demonstrate that intake of yoghurt 
is able to stimulate specific in vitro immune responses, like creation of cytokine, 
macrophage and lymph cell response. The effect of lactic acid bacteria varies according to 
each strain’s survival potential in the gastro intestinal tract, its ability to function in the acid 
environment of the gut, and its success in attaching to the intestinal mucosa. 
In the present study changes in the oxidative parameters are perhaps caused by immune 
system stimulation functions of both types of yoghurt. However, cytokine production, 
phagocyte activity, antibody production, or other immunostimulating activities of yoghurt 
products were not investigated in this study.  
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7   CONCLUSTION AND SUGGESTIONS 
 
The present study did not show any significant differences in lipid profiles within any 
group. The mean differences (T1-T3) between the yoghurt consuming groups and the 
control group showed a decrease in total cholesterol in both yoghurt groups, a decrease in 
total/HDL cholesterol ratio in both yoghurt groups, and an increase in HDL cholesterol in 
probiotic yoghurt group compared to the control. 
 
Changes in lipid profiles were observed in both probiotic and conventional yoghurt 
consuming groups compared to the control. We did not observe significant differences 
between lipid profile parameters in the two yoghurt groups. The fact that changes in lipid 
profiles were observed in both yoghurt consuming groups compared to the control group 
and that there were no differences between the two yoghurt groups, leads us to draw the 
conclusion that any hypocholesteromic effect might be due to the consumption of 
fermented milk and not necessarily the probiotic yoghurt. Both products had a positive 
effect on the lipid profiles of the subjects. 
 
Total antioxidant capacity was significantly lowered throughout the study in both 
conventional and probiotic yoghurt groups compared to the control group. Mean differences 
showed a significant decrease in TAC concentration for conventional yoghurt and an 
increase in MDA in the probiotic yoghurt group. The decrease in antioxidant and the 
increase in oxidant parameters indicate that the oxidative stress is probably the consequence 
of stimulating the immune system caused by the administration of yoghurt –probiotic or 
conventional. For these parameters as well, the observed effects are due to consumption of 
fermented milk.  
 
Suggestions for future studies: 
 
• To collect fecal samples in order to determine whether the ingested bacteria could also 
be found in the fecal samples. By measuring the fecal lactoflora, the effects of 
consuming the lactic acid bacteria on intestinal microflora could be assessed. 
 
 98  
• To measure the short chain fatty acids in the feces to assess the effect of lactic acid 
bacteria on production of the SCFA and to use it as a tool to evaluate the 
compliance. 
• To measure the effects of lactic acid bacteria on factors related to inflammation and 
immune system, such as interleukins, tumor necrosis factor-alfa, interferon gamma, 
CRP and other relevant factor. 
 
• To measure the effects of lactic acid bacteria on the activity of other antioxidant 
factors, enzymic and non-enzymic antioxidants parameters. 
 
• To study the effects of different strains of lactic acid bacteria on lipid profile and 
oxidative stress. 
 
• To conduct similar studies and evaluate the effects of long term administration of 
probiotic bacteria. 
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SUMMARY 
 
The effect of probiotic yoghurt on plasma lipids has been investigated in a number of 
studied, but the results are not conclusive. Furthermore, there are limited studies on the 
effects of probiotic yoghurt on oxidative stress in humans. The goal of this study was to 
compare the effects of probiotic yoghurt and conventional yoghurt on the lipid profiles and 
potentially oxidant and antioxidant parameters in healthy women. 
In a randomized trial, ninety females between 19-49 years old were allocated into three 
groups. The first two groups consumed either 300g/day probiotic yoghurt or conventional 
yoghurt for 6 weeks. The third group did not consume any yoghurt. Both conventional and 
probiotic yoghurts contained S. thermophilus and L. bulgaricus. The probiotic yoghurt was 
further enriched with cultures of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-
12.  Fasting blood samples, anthropometric measurements, and a three day dietary record 
were obtained at the baseline (T1), at the end of the 3rd week (T2), and at the end of the 6th 
week (T3). Lipid profile parameters were determined by enzymatic methods. 
Apolipoprotein A and B were analyzed by Immunoturbidometry method. Total antioxidant 
capacity and malondialdehyde were measured by spectrophotometric method, and oxidized 
LDL with Eliza. 
Results showed that there were no statistically significant differences in height, weight, 
BMI, age and nutrient intakes among the three study groups at the beginning of the study, 
and that there were no statistically significant changes throughout the study within any 
group.  
There were no significant changes in the lipid profile within any group throughout the study. 
Comparing mean differences (T1-T3) between yoghurt consuming groups and the control 
showed the following: no difference in triglyceride, LDL cholesterol, Apo A and B; 
decrease in cholesterol in both conventional (P=0.014) and probiotic yoghurt groups 
(P=0.002); decrease in total/HDL cholesterol ratios for both conventional (P=0.006) and 
probiotic yoghurt groups (P=0.000); increase in HDL cholesterol in probiotic yoghurt group 
(P=0.009).  
TAC concentration was significantly lower in the third week (T2) and sixth week (T3) of 
the study, in both conventional (T2<T1; P<0.01 & T3<T1; P<0.0001) and probiotic yoghurt 
groups (T2<T1; P<0.05 & T3<T1; P<0.0001) compared to the baseline values. There were 
no statistically significant differences in oxidized LDL and MDA among the three intervals 
of the study within any group. Comparing the mean differences (T1-T3) between yoghurt 
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consuming groups and the control showed significant decrease in TAC values for the 
conventional yoghurt group (P=0.002), an increase in MDA for the probiotic group 
(P=0.038), and no difference for oxidized LDL.  
This study showed that both products had a positive effect on the lipid profile and both 
yoghurts stimulated the immune system.   
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ZUSAMMENFASSUNG  
Die cholesterinsenkende Wirkung von probiotischem Joghurt wurde bereits in zahlreichen 
Studien untersucht und kontrovers diskutiert. Darüber hinaus haben sich bislang nur wenige 
Untersuchungen gezielt mit dem Einfluss von probiotischem Joghurt auf den oxidativen 
Stress befasst.  
Ziel der vorliegenden Studie war es daher, die Wirkung von probiotischem Johgurt auf das 
Lipidprofil und Parameter des oxidativen Stresses bei gesunden jungen Frauen zu erfassen. 
An der randomisierten Studie nahmen insgesamt 90 freiwillige Frauen im Alter von 19 bis 
49 Jahren teil, welche in drei Gruppen zu je 30 Probanden aufgeteilt wurden. Die Probanden 
erhielten über sechs Wochen täglich 300g konventionelles, 300g probiotisches oder kein 
Joghurt (Kontrollgruppe). Beide getesteten Joghurts beinhalteten S. thermophilus und L. 
bulgaricus, das probiotischen Produkt enthielt zusätzlich eine Mischkultur bestehend aus L. 
acidophilus, LA-5 und Bifidobacterium BB-12. Anthropometerische Messungen und ein 3-
Tage-Ernährungsprotokoll wurden durchgeführt, Nüchternblutproben zu Beginn der Studie 
(T1), drei (T2) und sechs Wochen (T3) nach regelmäßiger Joghurtaufnahme gesammelt. 
Sämtliche Blutlipidparameter wurden enzymatisch, Apolipoprotein A und B mittels 
Immunoturbidometrie bestimmt. Die gesamte antioxidative Kapazität (TAC) und 
Malondialdehyd (MDA) wurden spektrophotometrisch , oxidiertes LDL mittels ELISA 
analysiert.  Hinsichtlich Alter, Körpergewicht/-größe bzw. BMI und der durchschnittlichen 
Nährstoffaufnahme zeigten sich weder zwischen noch innerhalb der Gruppen im 
Studienverlauf signifikante Unterschiede. 
In Bezug auf das Lipidprofil konnte im gesamten Studienverlauf in keiner der untersuchten 
Gruppen eine signifikante Veränderung erfasst werden. Ein Vergleich der Differenzen der 
Ergebnisse (∆T) der drei Gruppen ließ nach 6-wöchigem Joghurtverzehr (T1-T3) keine 
nennenswerten Unterschiede der Konzentration an Triglyzeriden, LDL-Cholesterin, Apo A 
und B erkennen; Gesamtcholesterin nahm sowohl in der probiotischen (P=0.002) als auch in 
der konventionellen (P=0.014) Gruppe signifikant ab. Weiters konnte im Zeitraum T1-T3 
eine signifikante Reduktion des Gesamt-/HDL-Cholesterin Quotienten in beiden Gruppen 
(probiotisch: P=0.000; konventionell: P=0.006) beobachtet werden. Die Differenz der 
Plasmakonzentration an HDL-Cholesterin nahm im Untersuchungszeitraum (T1-T3) 
lediglich innerhalb der probiotischen Gruppe signifikant zu (P=0.009). 
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Verglichen mit den Ausgangswerten waren die Plasmalevel der TAC bereits nach 3- sowie 
nach 6-wöchigem regelmäßigen Joghurtkonsum sowohl in der probiotischen (T2<T1; 
P<0.05 & T3<T1; P<0.001) als auch in der konventionellen (T2<T1; P<0.01 & T3<T1; 
P<0.001) Gruppe signifikant erniedrigt. Hinsichtlich der Plasmakonzentrationen an 
oxidiertem LDL und  MDA konnte in keiner der Gruppen eine nennenswerte Veränderung 
während des Studienzeitraums eruiert werden. Ein Vergleich der Differenzen (∆T) dieser 
Parameter (im Zeitintervall T1-T3) zwischen den Interventions- und der Kontrollgruppe ließ 
eine signifikante Abnahme der TAC-Werte (p=0.002) im Kollektiv, welches 
konventionelles Joghurt verzehrt hatte, eine signifikante (P=0.038) Erhöhung der MDA-
Konzentration in der probiotischen Gruppe, jedoch keine nennenswerten Differenzen in 
Bezug auf oxidiertes LD erkennen. 
Die Studie zeigte, dass konventionelles sowie probiotisches Joghurt einen positiven Einfluss 
auf das Lipidprofil hat.                
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